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ABSTRACT 
Dendritic cell-mediated cancer immunotherapy employs several ways to engag  
tumor antigens. We have demonstrated both in pre-clinical animal studies and early 
clinical trials that dendritomas, highly purified hybrids between dendritic cells and tumor 
cells, are superior activators of anti-tumor immunity. In the present study, we examined 
the expression profile of several inflammatory chemokine and chemokine receptors of 
dendritomas by RNA microarray and real-time RT-PCR. The results indicate th t 
dendritomas made from immature DCs and tumor cells express higher levels of CCL3, 
CCL5, and CCL22 and lower levels of CCR2 and CCR5, which mimics LPS matured 
DCs, while dendritomas made from mature DCs and tumor cells show a reversed 
expression profile of these genes: decreased levels of CCLs and increased levels of 
CCRs. Our data support the notion that dendritomas made from immature DCs and tumor 
cells may be more effective in migration from the injection site to draining lymph nodes 
and therefore make them more effective in stimulating anti-tumor immunity. 
Morinda citrifolia (Noni) has been used as a folk remedy to treat a myriad of 
ailments, and is gaining in popularity as a modern dietary supplement to enhance the 
immune system. Recent studies have shown that Noni juice has anticancer activity. 
Studies from our lab demonstrated that fermented Noni juice not only prevents mouse 
sarcoma tumor development but also eradicates existing tumors. Fermented Noni can also 
directly engage dendritic cells with B cells. Since Noni contains a wide array of 
microorganisms, and upon fermentation, all but one are killed, it is presumed to contain a 
plethora of degraded microbial products that would serve as microbial stress signals.  We 
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hypothesized that Noni may activate dendritic cells by engaging their toll-like receptors 
(TLRs), and investigated genes associated with TLR signaling via real-time RT-PCR.  It 
was determined that Noni stimulates early low levels of inflammatory cytokines, 
followed by a latent upregulation of anti-inflammatory mediators.  Intriguingly, Noni also 
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1. LITERATURE REVIEW 
 
1.1.  The Immune System and Cancer 
In 1909 Paul Ehrlich first hypothesized our immune systems are capable of 
destroying initial emerging tumor cells (Ehrlich, 1909); however, reseach in this area 
had to await the developing field of immunology.  Nearly half a century later, Burnett 
and Thomas separately rebirthed the concept, eventually entitling it 
‘immunosurveillance’ (Burnet, 1957) (Thomas, 1959).   Experiments furiously followed 
aimed at supporting this ideology; however in the late 1970s immunosurveillance was 
abandoned due to limited understanding of nude mice at the time, and their inability to 
acquire higher amounts of spontaneous tumor formation (Dunn et al., 2002).  It is now 
acknowledged that nude mice have traceable amounts of αβ T cells as well as NK cells 
and other innate effectors.  Although several attempts were made to revive the 
immunosurveillance concept, it wasn’t until the mid to late 1990s that this area w s fully 
rejuvenated.  At that point it was further defined as ‘immunoediting’ in 2002 to more 
accurately describe the intricate balance between host defense againsttumor formation 
(elimination) and tumor immune evasion (escape) (Dunn et al., 2003). 
Immunoediting is described as a three-pronged process including elimination, 
equilibrium and escape (Dunn, 2003) as shown in Figure 1.1.  The first phase implies 
aberrant cells are constantly being transformed in a healthy host, and the immune system 
duly recognizes and eliminates these cells, hence the title ‘elimination’.  The second step 
requires the collection of several genetic modifications and a Darwinian-like selection of 
tumor cells that have lost their immunogenicity; however, these cells are kept in check by 
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innate immune cells and T cells, which amounts to a state of equilibrium. The selection 
of tumor cells that have lost immunogenicity can have detrimental effects.  It is these 
cells that are capable of escaping immune detection and have the potential to acquire ll 
seven hallmarks of cancer.  These hallmarks include: (1) self-sufficient, perpetuated 
growth signals, (2) alluding anti-growth signals, (3) inflammation, (4) uncontrolled 
replication, (5) evading apoptosis, (6) angiogenesis, and (7) metastasis (Colatta et al., 
2009; Montavi, 2009; Hanahan et al., 2000).  The successful treatment of cancer lies in 
the understanding of how the body initially recognizes and destroys tumor cells as well as 
how the immune system is commandeered for their protection and proliferation.  To 
eliminate cancer we must tip the scales back toward tumor elimination and minimize the 
factors allowing for its immune escape. 
 3
 
(Dunn et al., 2003. Ann Rev Immunol. 22: 329-360) 
 
Figure 1.1.  The three Es of cancer immunoediting.  Cancer immunoediting 
encompasses three processes. (a) Elimination corresponds to immunosurveillance.  (b) 
Equilibrium represents the process by which the immune system iteratively sel cts and/or 
promotes the generation of tumor cell variants with increasing capacities to survive 
immune attack.  (c) Escape is the process wherein the immunologically sculpted t mor 
expands in an uncontrolled manner in the immunocompetent host.  In (a) and (b), 
developing tumor cells (blue), tumor cell variants (red) and underlying stroma and 
nontransformed cells (gray) are shown; in (c), additional tumor variants (orange) that 
have formed as a result of the equilibrium process are shown.  Different lymphocyte 
populations are as marked.  The small orange circles represent cytokines and the white 
flashes represent cytotoxic activity of lymphocytes against tumor cells.
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1.2.  Cancer Immunotherapy 
Cancer immunotherapy hinges on the idea that we can manipulate the body’s 
immune milieu to favor tumor rejection.  This idea has developed into one of the most 
complex areas of cancer research.  With countless immune mediators like cytokines, 
growth factors and ‘danger signals’ (pattern-recognition receptor ligands), along with 
inimitable tumor cell profiles and microenviroments, it is impossible to identify one 
method of treatment effective for all cancer patients; hence the strong desire to advance 
the field of personalized cancer therapies (Hayden et al., 2009).  Several different types 
of immunotherapy are currently being studied for cancer treatment, includig monoclonal 
antibody therapy, radioimmunotherapy, and cell-based therapies (adoptive transfr of T 
cells and dendritic cell-based immunotherapy).  In 1997, Rituximab was the first 
monoclonal antibody approved by the FDA and it opened the door for cancer 
immunotherapies (Biotechnology Law Report, 1998).  Several more monoclonal 
antibodies were approved shortly after, and the first radioactive-labeled antibody was 
approved in 2002, Zevalin (Schilder, 2002).  The first vaccine for cancer prevention, 
Gardasil, was approved by the FDA in 2006 (Zawisza, 2006).  It is an immunization 
against certain HPVs that are associated with increased cervical cancer risk, and is the 
first drug specifically targeting inflammation-induced cancers.  There are, however, no 
FDA approved cell-based therapeutic cancer vaccines.  Here we will further examine 
dendritic cell-based therapies.  
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1.3.  Dendritic Cells  
DCs were first discovered in 1868 in the epidermis by Paul Langerhans, thus 
termed ‘Langerhans cells’ (Langerhans, 1868).  But it was more than a century before 
they were identified in other tissues and termed ‘dendritic cells’ by Steinman and Cohn in 
1973 (Steinman et al., 1973). Their scarcity proved them difficult to isolate and study.  
Consequently, it wasn’t until the early 1990s when DC purification improved and the first 
clinical trial for DC vaccines, published in 1995, showed promising results (Mukherji et 
al., 1995).  DCs are professional antigen-presenting cells poised to bridge innate and 
adaptive immunity while directing the balance of immunity and tolerance.  Th ir cross-
talk with natural killer (NK) cells (Fernandez t al., 1999), NKT cells (Fujii et al., 2002) 
and γδT cells (Conti et al., 2005) hastens innate immunity, while synchronistically 
presenting antigen to lymphocytes calling for acquired protection.  There is no other cell 
quite as capable of building this union.  Because of this unique property, many 
immunologists aim to harness the power of the dendritic cell for therapies from cancer 
treatment and prevention to reversal of type 1 diabetes (Giannoukakis et l., 2006) and 
AIDS vaccinations (Rinaldo et al., 2009).  Here we will focus on dendritic cell 
involvement with cancer.  The dendritic cell is instrumental in deciphering whether the 
immune system will eliminate tumor cells or tolerate their existence eventually leading to 
immune escape and malignant progression.  What determines this balance?  What factors 
influence the pivotal decision by the dendritic cell?  How can we harness their properties 
and utilize them against the very disease they are protecting?  The next decade of 
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dendritic cell-based cancer research will, with anticipation, unravel some of these 
mysteries. 
1.4.  Dendritic Cells and Cancer 
It has been established that the eradication of cancer cells requires both innate and 
adaptive immunity (Chaudhuri et al., 2009; Diefenbach et al., 2002), as well as activation 
of CD4+ and CD8+ T cells.  DCs are one of the primary cells capable of helping or 
hindering this process.  Once tumor cells have effectively escaped immune recognition, 
the tumor microenvironment favors tolerance, and the surrounding and infiltrating 
immune cells are often usurped for the tumors advantage.  Indeed, dendritic cells from 
cancer patients are functionally compromised  (Pinzon-Charry et al., 2005; Shurin et al., 
2006).  Often these DCs are inhibited in differentiation and maturation (Almand et l., 
2000), which could be due to the over-expression of STAT3 by tumor cells and 
subsequent upregulation of STAT3 by DCs, thus reducing their expression of co-
stimulatory and MHC class II molecules, or by the active recruitment of immature DCs to 
tumor tissues by way of tumor-produced chemokines (Bell et a ., 1999).  It has been 
shown that most tumors have higher numbers of DC infiltrates than surrounding healthy
tissues (Almand et al., 2000), so it would be advantageous to develop a treatment aimed 
at reprogramming the capability of DCs to recognize tumor cells as diseased cells, then 
process and present tumor antigen to surrounding innate and adaptive effector cells, 
under an immune stimulating environment. 
The most researched immune cells with tumoricidal properties are NK cells and 
cytotoxic T lymphocytes (CTLs).  NK cells recognize tumor cells via downregulation of 
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MHC class I molecules (in the presence of other activating signals) (Bubenik et al., 2004) 
and upregulation of stress-induced NKG2D ligands (Raulet et al., 2009).  Although NK 
cells are capable of direct tumor killing, DCs are involved in cross-talk with NK cells, 
which enhances NK cytotoxicity (Terme et al., 2008).  Although CD4+ T helper cells are 
now receiving more attention, cytotoxic T lymphocytes (CTLs) are the most researched 
cell in the adaptive immune branch accountable for anti-tumor responses.  DCs present 
antigen to CD8+ T cells via the endogenous pathway, or in the case of tumor antigens, by 
way of cross-presentation.  Based on in vitro experiments, there are seven defined modes 
of cross-presenting tumor antigens to T-cells  (Melief, 2008).  Transfer of antigens may 
occur by 1) phagocytosing antigens from necrotic or apoptotic tumor cells, 2) 
phagocytosing soluble antigens bound to heat shock proteins or other chaperonins, 3) 
ingestion of soluble proteins secreted from tumor cells, 4) uptake of exosomes secreted 
by tumor cells, 5) transfer of protein fragments through gap junctions, 6) direct nibbling 
of tumor cell plasma-membrane by DCs, and 7) ‘cross-dressing’, where dead tumor cells 
transfer MHC-I:peptide complexes directly to DCs.  Regardless of the method of cross-
presentation, if DCs are not properly stimulated, the resulting presentation of antigen to 
either CD4+ or CD8+ T cells induces tolerance via deletion or regulatory T cell 
stimulation (Melief, 2008).  It was demonstrated that both DCs and NK cells, after cross-
talk, were more effective at inducing Th1 and CTL responses in both human in vitro and 
in vivo mouse studies (Kalinski et al., 2005).  Thus, DCs play a vital role in recruiting 
innate and adaptive tumor-killing cells. 
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1.4.1.  Dendritic Cell Vaccines 
Dendritic cells used for cancer vaccines have been researched since the mid 
1990’s.  The first whole-tumor cell DC vaccine clinical trial used autologous DCs pulsed 
ex vivo with the patient’s own tumor antigens and administered subcutaneously (Hsu et 
al., 1996).  This first trial treated four patients with B-cell lymphoma and was largely 
successful.  All four patients had measurable antitumor cellular immune response and 
three patients had positive clinical responses.  As clinical trials began for other types of 
DC cancer vaccines, there were less encouraging results.  Broad spectrum sta istics of the 
outcome of all DC vaccine clinical trials yielded an overall clinical respon e of about 7%; 
however, other cancer vaccines not utilizing DCs (tumor cell-only, peptide-only or viral 
based vaccines) have only about a 3.5% response rate (Rosenberg et al., 2004).  To 
optimize the DC cancer vaccine, researchers have examined antigen loading strategies, 
maturation of DCs, and route of administration. 
1.4.2.  Antigen Loading Strategies 
Dendritic cell antigen loading strategies can be broken into three basic categories: 
RNA or DNA, peptide or protein, and whole tumor loading.  Nucleic acid loading of DCs 
is capable of utilizing the entire repertoire of tumor antigens, if total RNA is extracted 
from tumor cells (Kalady et al., 2004).  This method has the unique advantage of 
avoiding unwanted autoimmune reactions by subtractive hybridization with healthy ce l 
mRNA (Boczkowski et al., 1996).  Also, it is a promising therapy for patients without 
identified tumor-associated antigens (TAAs) or that lack sufficient tumor tissues to 
qualify for whole-tumor cell vaccine approaches.  Several drawbacks to this metod 
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include immunodominance, where viral vector antigens dampen the response to the 
tumor antigens; CTL targeting of the transfected DC eliminating these cell before 
eliciting the desired antitumor response; and a limited number of repeated vaccinations 
due to the anti-viral response (Mitchell t al., 2000) (Terando et al., 2007). 
Since most tumor antigens are actually self-derived, they are typicall considered 
weak antigens; therefore, with the discovery of TAAs (Lewis et al., 2003) many 
researchers began to pulse DCs with synthetic peptide antigens such as Her-2/neu, 
MAGE-1, CEA and many other TAAs (Disis et al., 1999; Hu et al., 1996; Morse et al., 
1999; Nair et al., 1999).  The upside to TAA-pulsed DC cancer vaccines is that these 
peptides could be synthetically manufactured, eliminating the need for patient tumor 
samples, and it reduces the possibility of autoimmune induction.  This technique is 
limited quite heavily, however, with the requirement of tumor immunogenic epitope 
identification and HLA-typing, and it only activates cellular immunity.  Some evidence 
has been given, however, to suggest that immunity against tumor cells not carrying the 
particular TAA is possible (Disis et al., 1999; Bellone et al., 1997).  To circumvent the 
need for defined peptide epitopes and MHC restriction, DCs have also been loaded with 
soluble recombinant or purified tumor proteins (Nonn et al., 2003; Shojaeian et al., 
2009).  These proteins are ingested by DCs via macropinocytosis with simple co-culture 
of DCs and proteins, and although they are primarily presented via MHC class I, they are 
not restricted to a single MHC class (Svane et al., 2003).  Overall, peptide and protein 
pulsing of DCs limits the pulsing antigen to defined TAAs.  Unless a potent immune 
attack follows, immunosculpting may occur to delete tumor cells with the defined TAAs, 
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but leave behind malignant cells not expressing these antigens, allowing for tumor escape 
once again.  Because of this, many scientists have pursued whole-tumor antigen 
strategies.   
It seems whole-tumor antigen pulsing of DCs would present many self-antigens 
that would interfere with potent antitumor immune responses, however clinical respons s 
of whole-tumor cell DC vaccines are comparable to peptide, protein and nucleic acid 
pulsed DCs  (Terando et al., 2007; Koido et al., 2007).  Whole-tumor antigen DC 
vaccines are capable of processing and presenting a wide array of tumor antigens, both 
known and unknown, to effector T cells, NK cells and other tumoricidal immune cells.  
This approach appears to have an advantage over the other methods of DC loading since 
it has the capacity to activate a much larger population of lymphocytes.  Within the field 
of whole-tumor antigen pulsed DC cancer vaccines, there are two main methods of 
deriving these antigens.  DCs can be pulsed with whole-cell tumor lysates (apoptotic r 
necrotic cells) or DCs can be fused to tumor cells.  There is evidence that DCs re more 
capable of antigen uptake, processing and presentation from necrotic tumor cells, rather 
than apoptotic cells (Scheffer t al., 2003; Sauter et al., 2000).  Contrary to this 
observation, apoptotic tumor cells elicited a much stronger antitumor T cell response than 
necrotic cells (Scheffer et al., 2003).  This dichotomy could be due to improper methods 
of ‘necrosing’ tumor cells.  In the body, necrotic tumor cells are in a hypoxic and stress-
inducing environment, which would increase the expression of stress signals that 
augment DC activation.  Most methodologies for preparing necrotic tumor cells ex vivo 
employ the freeze/thaw method.  This method has recently been shown to diverge from 
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natural necroses in that the cells become necrotic in the absence of stress (Hatfield et al., 
2008).  The lack of stress signals from the cells may dampen their immunogenicity.  
Indeed, it was observed that freeze/thaw lysates were not capable of proper costimulatory 
molecule and MHC class II induction and suppressed Toll-like receptor maturation of 
DCs (Hatfield et al., 2008). The obvious drawback for this method of antigen loading (as 
well as total tumor RNA transfection of DCs) is the potential to incite autoimmunity; 
however, clinical trials to date have not observed detectable autoimmune reactions (Zhou 
et al., 2009; Homma et al., 2006).  Also, there must be a sufficient amount of tumor 
tissue available for this therapy, limiting it to patients with solid tumors large enough for 
surgical removal and subsequent x vivo cell culture.  
There have been numerous attempts to define whether tumor cell lysate pulsing or 
DC-tumor cell fusions are superior.  So far there is more supporting evidence for th 
efficacy of DC-tumor cell fusions rather than lysate-pulsed DC vaccines (Galea-Lauri et 
al., 2004; Shimizu et al., 2004; Kao et al., 2005); however, the rationale behind this has 
not yet been determined. It is possible that the act of fusion induces enough of a stress
response in DCs that enhances their immunogenicity.  Dendritic cell-tumor cell fusions 
have received much attention for DC-based cancer vaccines since they are capabl  of 
presenting the entire array of tumor antigens, both known and unknown, to T cells via 
MHC class I and II molecules. There are two methods for creating DC-tumor 
hybridomas:  electrofusion and chemical fusion with polyethylene glycol (PEG).  
Electrofusion represents a better choice for designing DC fusion vaccines sinc  there is 
more control over the process and it gives more consistent fusion rates from day-to-day 
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and between users than PEG-fusion.  PEG fusion tends to be highly unpredictable, giving 
rise to varying fusion rates critically dependent on constant temperature, precise 
administration and different administrators.  PEG fusion would greatly benefit from an 
automated system.  Regardless of the method of creating DC-tumor fusions, these cells 
integrate their cytoplasm, but have separate nuclei, allowing for both cells to be partially 
functional and produce TAAs from the tumor cell which can be complexed with DC-
derived MHC molecules (Koido et al., 2004).  Several studies have used allogeneic DCs 
fused with autologous tumor cells with promising results (Zhou et al., 2009; Lei et al, 
2009); however, one of the clear disadvantages of using allogeneic DCs is the limitation 
of eliciting only CD8+ T cell responses.  It is becoming more widely acknowledged that 
CD4+ T cells are necessary for the ultimate antitumor response (Marzo et al., 2000; 
Tanaka et al., 2005).  New methods of combining DC-tumor fusions with adjuvants, such 
as OK-432 (Koido et al., 2007) and HSP70 (Karyampudi et al., 2008), or inhibiting T 
regulatory cells (Li et al., 2007) suggest even more effective strategies for DC cancer 
vaccines.   
1.4.3.  Maturation State of Dendritic Cells for Fusion Vaccines 
The maturation state of DCs for cancer vaccines has been an area of intense
scrutiny over the last several years.  In general, immature dendritic cells are more 
effective at antigen uptake (Rovere et al., 1998) and mature dendritic cells are capable of 
presenting these antigens to effector cells and eliciting stronger immunologic responses 
(Guermonprez et al., 2002).  In fact, the presentation of antigens by immature dendritic 
cells often skews the immune response toward tolerance (Steinman et al., 2003).  So, 
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presumably, immature DCs would be most effective to utilize when pulsing or fusing
with antigen; however, the vaccine end product should consist of properly matured 
dendritic.  This clear distinction is not as defined in animal and clinical settings, however.  
Indeed, immature DCs were demonstrated to induce potent cytolytic activity by 
splenocytes, when fused with MC38 tumor cells (Takeda et al., 2003).  And other 
experiments have shown no attributing difference between the effectiveness of immature 
or mature DC-tumor fusions (Vasir et al., 2008), while others clearly argue the necessity 
of mature DCs for vaccine therapy (Baggers et al., 2000).  Although general upregulation 
of CD80, CD86, CD83, CD40 and MHC class II molecules correspond with a maturing 
DC phenotype, the necessary profile of these proteins and the extent to which they must 
be expressed for maximum efficacy has not yet been fully elucidated.  Thus, the plasticity 
of DCs has been a complicating factor in designing optimal DC vaccines. 
1.5.  Dendritic Cells and Chemokines 
Chemokines are small chemotactic cytokines that direct the trafficking of immune 
cells, regulate angiogenesis/angiostasis, and can be involved in the promotion of 
metastasis.  Here we will focus on their chemotactic effect on immune cells, specifically 
dendritic cells.  During an infection or inflammatory response, inflammatory chemokines 
are rapidly produced (CCL2, CCL4, CCL5, CXCL8) (Sallusto et al., 1999).  Circulating 
immature DCs express inflammatory chemokine receptors (CXCR1, CCR1, CCR2, 
CCR5) (Allavena et al., 2000), which allow recruitment to sites of inflammation to take 
up antigen and aid the immune response against infection.  As shown in Figure 1.2, when 
DCs reach these sites of inflammation and are exposed to maturation stimuli (CD40L, 
 14
PRR ligands, inflammatory cytokines), they undergo maturation, decreasing their antigen 
capturing abilities and increasing MHC class I and II and costimulatory m lecules, with a 
concomitant decrease in inflammatory chemokine receptor expression (Dieu et al., 1998).  
This downregulation of CCRs occurs at both transcriptional and post-transcriptional 
levels and is accompanied by an increase in CCR7 expression (Hirao et al., 2000).  This 
increase in CCR7 and decrease in inflammatory CCRs allows the mature DCs to migrate 
away from the inflamed site toward nearby draining lymph tissues.  CCR7 binds CCL19 
and CCL21, which are constitutively produced on endothelial and stromal cells in B/T-
cell areas of the lymph (Rot e al., 2004).  This upregulation of CCR7 on mature DCs 
brings them into close contact with lymphocytes, specifically T cells, to present antigen 
via MHC class I or II (Ebert et al., 2005).  This is the typical process of DC activation, 
LN migration and presentation of antigen to T cells, and DC vaccines must be capale of 




Figure 1.2.  Chemokine receptor expression from pre
cell precursors in peripheral blood express CCR2.  These cells, once stimulated with GM
CSF, IL-4, Flt-3L or other stimulants, differentiate into immature DCs expressing 
inflammatory chemokine receptors CCR1, CCR2, CCR5, CCR6, CXCR1 and CXCR2. 
These chemokine receptors allow recruitment of immature DCs to sites of inflammation, 
following the inflammatory chemokine gradient.  Once arriving at inflamed tissues, 
danger signals and inflammatory cytokines permit DC maturation.  
undergo autodesensitization of inflammatory chemokine receptors, with concomitant 
expression of inflammatory chemokines.  Shortly thereafter, mature DCs express CCR7 
and CXCR4, which allow for their departure from inflamed tissues (since they no longer 
express inflammatory chemokine receptors), and recruitment to secondary lymph tissues.
15
-DC to activated DC.
Maturing DCs 
 





1.6.  Toll-like Receptors (TLRs) 
The immune system is divided into two modes of protection:  innate immunity 
and adaptive or acquired immunity.  The innate branch was long thought to induce non-
specific immunity, while the adaptive branch generated specific immune reactions via T- 
and B-lymphocytes.  The ‘nonspecific’ definition of the innate immune system is being 
reconsidered as it is becoming increasingly more apparent that there is quitea deal of 
specificity involved.  This modification of our understanding of innate immunity has 
been primarily driven by the expanding knowledge of pattern-recognition receptors 
(PRRs) and their ligation with pathogen-associated molecular patterns (PAMPs), as well 
as the continued discovery of novel PRRs and PAMPs.  PRRs are a broad class of 
receptors that bind stress signals including microbial and synthetic components.  They 
include TLRs, CD14, NOD-like receptors (NLRs), RIG-like receptors (RLRs), 
complement receptors, and C-type lectins (Palm et al., 2009).  The subgroup TLRs has 
probably received the most attention.  TLRs have been highly conserved throughout 
evolution, attributing to their biological importance.  They are a subfamily of the larg r 
superfamily including IL-1Rs.  Both IL-1Rs and TLRs have cytoplasmic TIR (Toll/IL-
1R) domains containing three signaling motifs.  However, their extracellular (EC) regions 
differ: IL-1Rs have three immunoglobulin-like domains and EC TLR regions consist of 
stacks of leucine-rich repeats (LRRs) that are arranged into a horseshoe structure 
(Iwasaki et al., 2004; Akira et al. 2004).  To date there are ten TLRs identified in humans 
and thirteen in mice.  TLRs 1-10 are similar between human and mouse; however, the 
functionality of murine TLR8 is questioned (Gorden et al., 2006).  TLR1, -2, -4, -5 and -6 
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are membrane-bound and TLR3, -7, -8 and -9 are located on endosomes within the cell, 
which is expected since they recognize nucleic acid structures (most often viral).  Here 
we will focus on murine TLRs. 
1.6.1.  Dendritic Cells and TLRs 
Dendritic cells are important mediators of TLR signaling since they are pois d at 
the interface of innate and adaptive immunity.  TLR expression on DCs greatly depends 
on the DC subset.  CD4+ DCs express all murine TLRs except TLR3; CD8+ Cs lack 
TLR5 and TLR7; CD4-CD8- DCs express TLRs1-9 (Edwards et al., 2003; Iwasaki et al., 
2004); and BMDCs express all TLRs except TLR3 and TLR7 (Dearman et al., 2009).  
Interestingly, plasmacytoid DCs lack TLR3 which is one of the TLRs most prminent in 
IFN-β production.   It makes sense that different DC subsets have different TLR profiles 
since they will encounter particular pathogens depending on their anatomical location.  
This is yet another way the immune system regulates tailored immune responses. 
1.6.2.  Tailored Immune Responses by TLRs 
It is becoming increasingly evident that the complexity of the innate immune 
system may reach far beyond that of the adaptive.  Each of the TLRs, although similar,
induces slightly different combinations of cytokine, chemokine and other immune 
mediator profiles.  Yet another level of regulation involves refined signaling with 
different combinations of TLR ligands.  These responses may also vary depending on the 
type of cell they induce.  One such way of regulating TLR responses is the recruitm nt of 
different adaptor proteins to the TLR cascade (Re et al., 2004).  Even within one TLR 
ligand, there can be subtle differences that call for quite different responses.  For 
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example, it was recently discovered that three different forms of polyriboinosinic-
polyribocytidylic acids (poly I:C) elicit three different gene profiles in phenotypically 
mature DCs (Avril et al., 2009).  Simultaneous activation of different TLRs can enhance 
or even inhibit TLR signaling pathways.  It has been shown that TLR8 inhibits TLR7 and 
-9 and TLR9 inhibits TLR7 in HEK293 cells (Wang et al., 2006); this, however, has not 
been confirmed in vivo.  In essence, different combinations of TLR expression on a 
particular cell type, the number of different signaling pathways that can be induced by 
each TLR, and the synergistic or antagonistic effects of multiple TLR ligand induction 
may induce millions of different gene profile combinations.  Indeed, the complexity of 
innate immunity intensifies as our knowledge of the field expands. 
1.7.  Inflammation and Cancer 
There has been long standing evidence for the involvement of inflammation and 
cancer.  Infectious diseases causing chronic inflammation account for approximately one-
fourth of all cancers in developed countries (Balkwill et al., 2001).  Helicobacter pylori, 
Hepatitis B virus, Hepatitis C virus, and Epstein-Barr virus infections are all major 
contributing risk factors for gastric cancer, hepatocellular carcinoma, and 
lymphoproliferative disorders, correspondingly (Coussens, 2002).  It was suggested that 
these microbes encouraged oncogene activation, but it has since been recognized that 
chronic inflammation is a major player in increased risk factors for certain cancers 
(Coussens, 2002).  Most common cancers associated with chronic inflammation include 
the aforementioned as well as cervical (Castle et al., 2001), lung (Lee t al., 2009), 
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bladder (Michaud, 2007), esophageal (Deans et al., 2006), pancreatic (Farrow et al., 
2002) and prostate cancers (Palapattu et al., 2005). 
Along with the correlation between chronic inflammation and cancer, there is also 
an association of decreased risk for certain cancers with the prolonged used of NSAIDs 
(non-steroidal anti-inflammatory drugs), which is linked to the inhibitory effect on NFκB 
transcription factors (Garber, 2003).  Aspirin, the archetype of NSAIDs, has been 
demonstrated to play a protective role against colorecal cancer (Dube et al., 2007), 
esophageal and gastric cancers (Gonzalez-Perez et al., 2003), and breast cancer (Zhao et 
al., 2009).  Karin and Greten pointed out that not only does long-term use of NSAIDs 
correlate with decreased risk for certain cancers, but the use of ginseng, green tea, 
resveratrol and curcumin also benefit the reduction of cancer occurrence (Karin et al., 
2005).  These compounds all share inhibitory activities on the NFκB family of 
transcription factors that are responsible for inducing many of the inflammatory 
cytokines and chemokines (Bharti et al., 2002).  So it seems as though inhibiting 
inflammation via downregulation of NFκB may be the key to decreasing risk factors for 
inflammation-associated cancers. 
NFκB represents a family of five transcription factors including NFκB1 
(p105/p50), NFκB2 (p100/p52), RelA (p65), RelB and c-Rel.  The latter three are all 
capable of binding DNA, however, p105 and p100 must be cleaved from NFκB1 and 
NFκB2, respectively, to release the corresponding DNA binding subunits p50 and p52 
(Caamano et al., 2002).  Different combinations of NFκB subunits dimerize to achieve 
tailored responses to specific stimuli.  All five members, p50, p52, RelA, RelB and c-Rel, 
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contain Rel homology domains (RHD) that are responsible for dimerization and DNA 
binding; and the RHD is also where inhibitory IκB family members interact with NFκB 
subunits (Ghosh et al., 1998).  NFκB dimers are held inactive in the cytoplasm by IκB
proteins.  The primary inhibitory proteins include IκBα, IκBβ, IκBε, p100 and p105.  In 
order for the NFκB dimers to travel to the nucleus, they must be released from the IκBs. 
Upon appropriate stimulation, IκB kinases (IKKs) are activated which in turn 
phosphorylate IκBs.  There are three main subunits of the IKK complex, IKKα, I Kβ 
and IKKγ (NEMO).  Typically, IKKβ is involved with inflammatory cascades, whereas 
IKKα is primarily implicated in morphogenic signaling.  NEMO is the regulatory subunit 
of this complex in that its activation is required for IKKα and IKKβ phosphorylation of 
IκBs (Rothwarf et al., 1998).  IKKs phosphorylate IκBs making them targets for 
ubiquitination and subsequent degradation, releasing the NFκB subunits and allowing 
their nuclear translocation. 
Tollip, an adaptor protein first discovered in the IL-1R pathway (Burns et al., 
2000), has since been identified as an inhibitory protein for certain TLR pathways (Zhang 
et al., 2002).  Induction of IL-1R and most TLRs stimulates pro-inflammatory mediators, 
hence Tollip is involved in minimizing or suppressing the induction of inflammation.  It 
does not act via direct NFκB inhibition, but rather acts upstream to inhibit IRAK1 (Zhang 
et al., 2002).  Upon stimulation of TLR ligands, particularly TLR2 and TLR4, IRAK4 is 
brought into close proximity with IRAK1 and phosphorylates IRAK1 causing the releas  
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of Tollip and downstream activation of the TLR pathway.  It acts in a similar manner in 
IL-1R signaling, to suppress IL-1 induced signaling (Burns et al., 2000). 
NFκB inhibitors are constantly being researched in efforts to develop drugs to 
treat such diseases as asthma, autoimmune, arthritis and certain inflammation-associated 
cancers.  Many plant-based compounds have been identified to interfere with the 
inflammatory pathway by specifically inhibiting NFκB activation.  These include many 
antioxidants such as curcumin, quercetin, epigallocatechin 3-gallate (EGCG), fungal 
products and many other compounds (Nam, 2006).  Curcumin has been shown to inhibit 
NFκB in a dose-dependent manner, and its mechanism of action may by hinged to the 
induced expression of HSP70 (Dunsmore et al., 2001).  Besides its inhibition of NFκB 
signaling, quercitin has also been shown to reduce constitutive NFκB activation in human 
prostate cancer cells (Nam, 2006).  EGCG, the most reputable biologically active 
component of green tea, inhibits NFκB by inhibiting degradation of IκB via inhibition of 
IKK activity in both cancer cells and normal cells (Yang et al., 2001).  Three fungal 
products, cycloepocydon, gliotoxin and panepoxydone, are known NFκB inhibitors.  
Umezawa and colleagues tested these three NFκB inhibitors for their potential to reverse 
the constitutive NFκB-induced protection from apoptosis in tumor cells, and their results 
were promising for cancer therapies (Umezawa et al., 2000).  These compounds show 




1.8.  Morinda citrifolia (Noni) 
Morinda citrifolia (Noni) has been used for centuries to treat an array of maladies.  
It is a small evergreen tree native to South Asia, with elongated leaves, white tubular 
flower clusters, and greenish fruits that ripen to whitish-yellow.  Its popularity has been 
on the rise particularly since the relaxed FDA guidelines for dietary supplements (Wang 
et al., 2002) and the advent of Tahitian Noni International.  Because of this, scientific 
research on Noni has expanded greatly over the last decade.  The main objectives are o 
ensure its safety as a food product and to identify components responsible for its 
purported effects.  Although its oldest uses primarily involved topical application of 
leaves and roots, the fruit has been more popular for modern usage (Pawlus et al., 2007).  
Fermented Noni is the most traditional method of consumption.  Its fruits are harvested, 
collected into glass jars and allowed to ferment for several hours up to several weeks 
(Dixon et al., 1999).  The documented, scientifically researched effects of Noni include 
anti-inflammatory, antiangiogenic, anticancer, antibacterial and antioxidant.  Here we 
will focus on the applications and components of Noni fruits and their aforementioned 
effects. 
Noni has been reported to modulate immune cells and has been implicated in 
enhancing the adaptive immune response by activating T and B cells.  There is growing 
concern about the administration of antibiotics to production animals, therefore, new 
methods for boosting immune systems of livestock has been hotly pursued.  Since Noni 
has long standing reports of being an immunomodulator, it is not surprising that it is 
being considered for the treatment of neonatal and newborn calves.  In one such study, 
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Noni was used as a bactericidal supplement for calves and delivered promising results 
with enhanced killing of Escherichia coli (Schafer et al., 2008).  There is also a patent on 
Noni formulations for immunomodulation of T cells in neonatal stock animals, an 
important mediator for resisting bovine RSV, a common cause for death of newborn 
calves (Darien et al., 2007).  A study in 2008 revealed the immunomodulation of B cells 
as a result of direct DC stimulation with fermented Noni exudate.  Murine DCs were 
treated with Noni for 24 hours, washed, then cocultured with splenocytes.  Interestingly, 
the population of proliferative splenocytes was primarily B cells; and not only were B 
cells stimulated to divide, but they also underwent differentiation and Ig class switching 
(Zhang et al., 2009).  Thus, Noni has obvious effects on the adaptive branch of immunity 
and may play an important role in future livestock management. 
Traditional uses for Noni have included treatment for sprains, menstrual 
difficulties, arthritis, asthma and general swelling (Wang et al. 2002), all of which are 
associated with inflammation.  One possible mechanism of the anti-inflammatory effects 
of Noni has been explained by Palu and colleagues.  Here it was reported that Noni 
activates cannabinoid receptors, specifically CB2, in a dose-dependent manner (Palu et 
al., 2008).  CB2 activation is associated with anti-inflammation.  Also, Morinda 
morindoides, a close cousin of Noni, was shown to inhibit complement factors, which 
substantiates its use for treating rheumatic pains (Cimanga et al., 2003).  These two 
mechanisms are only part of Noni’s arsenal for inducing anti-inflammatory effects; the 
others may be attributed also to its antioxidant properties. 
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Antioxidant activity of Noni has been credited to several compounds, namely 
coumarin derivatives, scopoletin, 7-hydroxycoumarin (7-HC) and 4-HC, a novel 
anthraquinone, two novel iridoid glucosides, and quercetin (Ikeda et al., 2009).  
Scopoletin is a well kown antioxidant and has been attributed to antimicrobial and anti-
inflammatory activities (Deng et al., 2007).  The novel anthraquinone (2-methoxy-1,3,6-
trihydroxyanthraquinone) was found to be nontoxic at high doses and nearly 40 times 
more potent at reducing quinone than the positive control (Pawlus et al., 2005).  A 
detailed study by Deng and colleagues revealed eight compounds of Noni that inhibited 
lipoxygenase.  These included scopoletin and two novel lignans, a lactone and (+)-3,3’-
bisdemethyltanegool (Deng et al., 2007).  In 2005, a novel lignan, Americanin A, was 
identified in Noni and it was confirmed to be a potent antioxidant (Su et al., 2005).  
Based on the recent detailing of the chemical constituents of Noni and their antioxidant 
activities, science is able to start backing the claims held by Noni users for centuries. 
Lastly, Noni has received much attention for its antiangiogenic and anticancer 
properties in both animal models and clinical settings; however, the mechanisms 
underlying this effect are largely unknown.  The first attempt to identify the component 
of Noni responsible for its antitumor activities described a water-soluble, ethanol-
precipitable, polysaccharide-rich substance from Noni fruit as the immunomodulator 
(Hirazumi et al., 1999).  Importantly, this report was the first to note the enhanced 
chemotherapeutic activities of Noni.  Shortly thereafter, Wang and Su identified Noni to 
inhibit DMBA-DNA adduct formation (Wang et al., 2001), implicating its protective role 
in chemically induced cancers.  In 2003, Furusawa and Hirazumi expanded their research 
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to demonstrate the antitumor properties of Noni precipitate (ppt) were dependent o  
macrophages, NK cells and T cells and extended its synergistic effects with even more 
chemotherapies (Furusawa et al., 2003).  Also in 2003, Noni was tested for 
antiangiogenic effects and was found to inhibit new vessel sprouts at 5% concentration 
and induce vessel degeneration at 10% concentration (Hornick et al., 2003).  The most 
recent account of antitumor activity by Noni confirmed the necessity of NK cells and T 
cells for tumor eradication (Li et al., 2008).  Noni was shown to be effective at both 
cancer prevention and treatment within S180 and Lewis Lung tumor models.  It is worth 
noting, mice that cleared tumor burden were rechallenged after two months, and all 
rejected the tumors; five months later the same mice were challenged again and 15 of 16 
mice rejected the tumors.  The strong animal evidence for anticancer properties of Noni 
has encouraged its research, and with time we are beginning to understand its 
mechanisms of action. 
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2.1.  Abstract 
Dendritic cell-mediated cancer immunotherapy employs several ways to engag  
tumor antigens.  We have demonstrated in both pre-clinical animal studies and early 
clinical trials that dendritomas, highly purified hybrids between dendritic cells (DC) and 
tumor cells, are superior activators of anti-tumor immunity.  It has been argued, however, 
that DC vaccines may be dysfunctional in lymph node migration.  In the present study we 
examined inflammatory chemokine and chemokine receptor expression as well as other 
maturation induced genes in dendritomas produced from either immature or mature DCs 
in order to shed light on their capacity to migrate from injection sites to draining lymph 
nodes and elicit an appropriate immune response. RNA microarray analysis was u ed to 
identify gene expression profiles for inflammatory chemokines and receptors and other 
maturation induced genes within dendritomas, lysate-pulsed dendritic cells, immature 
DCs and mature DCs.  Gene regulation was confirmed with relative quantification, real-
time RT-PCR in a separate experiment. We found that fusion of immature DCs to tumor 
cells initiates maturation with respect to inflammatory chemokines, chemokine receptors 
and other maturation induced genes in a similar pattern as LPS matured DCs.  
Interestingly, we saw a reversed gene profile when mature DCs were fused to tumor cells.  
LPS matured DCs displayed the chemokine repertoire expected with DC maturation; 
however, once fused to tumor cells, these chemokines and other maturation induced 
genes reverted to levels comparable to immature DCs.  It appears that mature DCs used 
for dendritoma production result in a de-mature phenotype. Our results indicate that 
dendritomas from immature DC/tumor cell fusions may be more effective in migration 
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from injection site to draining lymph nodes and, therefore, would be more effective in 
stimulating anti-tumor immunity. 
2.2.  Introduction 
Dendritic cells (DC) are professional antigen presenting cells, which play a vital 
role in stimulating immune responses against infections and tumor cells (Banchereau et 
al., 1998; Hart, 1997; Dunn et al., 2002).  DC-mediated cancer immunotherapy is aimed 
at picking up where the host immune system failed by presenting tumor antigens o innate 
and adaptive effector cells, thus stimulating anti-tumor immunity for immediat  therapy 
and latent protection (Ullrich et al., 2008; Banchereau et al., 2002; Steinman et al., 
2006).  Three basic approaches have been employed to engage DCs with tumor antigens: 
tumor antigen pulsing, genetic modification with tumor antigen genes or RNA, and 
DC/tumor fusion (Schuler et al., 2003; Svane t al., 2003).  Although all three 
approaches have been widely utilized and have successfully increased tumor-antigen 
reactive T cells in periphery, the DC/tumor hybridoma vaccine has proved more effective 
since this strategy provides a broader diversity of known and unknown tumor antigens as 
well as MHC class I and MHC class II antigens to the immune system (Ward et al., 2002; 
Shimizu et al., 2004). 
Most DC hybridoma studies have utilized fusion mixtures as a vaccine due to the 
lack of selective markers on fused DC/tumor cells to purify hybrids from the fusion 
mixture (Haigh et al., 1999).  The immune response stimulated by this mixture is 
compromised due to the presence of large numbers of unfused cells or self/self fused 
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cells.  In order to solve this problem, we developed a novel hybrid purification 
technology that instantly purifies DC/tumor hybrids from the mixture (Holmes et al., 
2001).  Animal studies demonstrated that highly purified DC/tumor hybrids, or 
dendritomas (DT), are superior activators to stimulate anti-tumor immunity compared 
with fusion mixtures (Li et al., 2001).  Several clinical trials using dendritoma vaccines 
have been conducted; and data shows that DT vaccines stimulate anti-tumor immune 
responses in some patients and demonstrate observable clinical responses (Wei et al., 
2006; Wei et al., 2007). 
On the other hand, although most DC hybridoma vaccines were effective in 
preclinical animal studies, clinical trials have shown less encouraging results (Gong et 
al., 2008).  Consequently, an important field in DC mediated cancer immunotherapy is to 
understand and solve the inconsistencies between animal studies and human clinical 
trials.  The increase of regulatory T cells and tolerogenic DCs found in tumors after DC 
vaccine administration are two of the major factors suppressing anti-tumor imunity 
(Steinman et al., 2003; Li et al., 2007; Dannull et al., 2005).  Others include DC 
procurement, route of administration, and tumor microenvironment (Melief et al., 2008; 
Grover et al., 2006).  The overall belief is that DCs must be presented with maturation 
stimuli and tumor antigen, administered through an appropriate route for different cancers 
with mediators aiding their lymph node migration, and have the capacity to process and 
present both MHC I and II peptides in order to acquire therapeutic and long-term 
protective immunity (Ueno et al., 2006).  Much research has been done to progress DC 
vaccination in most of these areas; however, information on the migratory capacity of DC 
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vaccines is still needs attention.  It is imperative to understand the factors involved in the 
migration of dendritomas, and other DC vaccines, to the draining lymph nodes where 
they encounter and activate effector T cells. 
Inflammatory chemokines, such as macrophage inflammatory protein 1alpha 
(MIP-1α) and RANTES (CCL3 and CCL5, respectively), are predominantly located at 
nonlymphatic sites of inflammation where they recruit immune cells to participate in 
antigen presentation and recognition to ultimately elicit a cell-mediated response to 
infection or tumor cells.  Immature DCs (iDC) typically express inflammatory chemokine 
receptors CCR1, CCR2 and CCR5 which bring them into contact with antigens at 
inflammatory sites (Sozzani et al., 2000).  Once antigen uptake has ensued, DCs rapidly 
increase production of inflammatory chemokines and lose responsiveness to these CCLs, 
a process called autodesensitization (Sallusto et al., 2000), allowing for reverse 
transmigration of activated, mature DCs (mDC) into secondary lymphoid tissues where
they present antigen to effector cells.  Clearly, the completion of this process is ssential 
for effective DC vaccines.  In the present study, in order to understand whether 
dendritomas are capable of effective migration to secondary lymphoid tissues, we 
examined the regulation of key chemokines and chemokine receptors along with several 
maturation induced genes.  Our microarray and real-time RT-PCR results demonstrate 
that fusing tumor cells to iDCs matures them with respect to ccr and ccl expression, while 
fusing tumor cells to mDCs causes the reversal of ccr and ccl expression by mDCs.  Our 
results implicate immature DCs as better choice for dendritoma production, and a 
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migratory mediator adjuvant may be needed when mature DCs are used for dendritoma 
production. 
2.3.  Materials and Methods 
2.3.1.  Mice and Tumor Cells 
Female C57BL/6J mice at 6-8 weeks of age were purchased from Jackson 
Laboratories (Bar Harbor, ME) and housed in our pathogen-free animal facilities.  
Animal experiments were carried out in accordance with both Guidelines for the Care 
and Use of Laboratory Animals (NIH Publication number 85-23) and institutional 
guidelines. Murine acute myeloid leukemia cell line C1498 and murine melanoma cell 
line B16F0, both C57BL/6J-derived, were maintained in complete DMEM (Gibco BRL, 
Grand Island, NY) supplemented with 10% FBS (Hyclone, Logan, UT) and 50 µg/ml
gentamicin (Gibco BRL) at 37 °C in a humidified atmosphere of 5% CO2.
2.3.2.  Dendritic Cells 
Bone marrow derived DCs were cultured as previously described (Lutz et al., 
1999).  Briefly, bone marrow cells flushed from C57BL/6J mouse femurs and tibiae with 
RPMI-1640 (Gibco BRL) were filtered through 40-µm nylon cell strainers. After the 
removal of RBCs by ACK lysate (Lonza, Allendale, NJ), the remaining cells w re 
resuspended in DC medium containing RPMI-1640  supplemented with 10% FBS, 50 
µg/ml gentamicin, and 20 ng/ml rmGM-CSF (Sigma, St. Louis, MO) and plated at 4-
5x106 cells/10 ml in a 100-mm tissue culture dish.  On day 4, 10 ml fresh DC media was 
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added to each dish.  On day 8, non-adherent and loosely adherent cells were harvested, 
washed with RPMI-1640 and replated in fresh DC medium containing 10 ng/ml rmGM-
CSF with or without 100 ng/ml LPS (Sigma).  On day 10, non-adherent and loosely 
adherent cells were collected for further studies.  
2.3.3.  Pulsing DCs with Tumor Lysate 
B16F0 cells were collected and resuspended in a conical tube in 1x PBS at a 
concentration of 1x107cells/mL.  The tube with cell suspension was immersed in a dry-
ice/methanol bath for approximately 3 minutes.  Once frozen, the cells were placed in a 
37°C water bath with gentle agitation and thawed completely.  The process was repe ted 
for a total of four freeze/thaw cycles.  The cells were then centrifuged at 15,000 x g for 
10 minutes at 20°C and supernatant was collected.  Protein concentration was determined 
using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA).  Either immature DCs (iDC) 
or LPS matured DCs (mDC) were incubated with 100µg/mL tumor protein lysate 
overnight.  Pulsed DCs (LPiDC or LPmDC) were then centrifuged at 300 x g to collect 
cells but discard lysate in the supernatant.  Cells were washed three times in 1x PBS prior 
to RNA extraction. 
2.3.4.  Cell Staining and Fusion 
DCs and tumor cells were stained green and red, respectively, using PKH67-GL 
or PKH26-GL kits (Sigma) according to manufacturer’s protocol.  Stained cells w re 
washed thrice to remove unbound dye and tumor cells were irradiated with 50 Gy. Tumor 
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cells and DCs were fused at a ratio of 1:1 or 1:2 using a 50% PEG 10% DMSO solution 
(Sigma).  After fusion, cells were incubated overnight in DC medium.  
2.3.5.  FACS Sorting 
The fusion mixtures were harvested (both adherent and non-adherent) and 
resuspended in PBS at a concentration of 1x107 cells/ml.  Cells were sorted on a BD 
FACSCalibur (Becton Dickinson, San Jose, CA) according to the dual fluorescent colors.  
Sorted cells, labelled as dendritomas (DT), were resuspended in DC medium and 
incubated overnight with or without 100 ng/ml LPS prior to RNA extraction.  
Dendritomas exhibited both green and red fluorescence and purity was greater than 95 
percent. 
2.3.6.  Microarray 
LPiDC, LPmDC, DT, DC, and tumor cell RNA was extracted using 
ArrayGradeTM Total RNA Isolation Kit (SABiosciences, Frederick, MD) and was sent 
for pathway-focused GEArray service using mouse Dendritic and Antigen Presenting 
Cell Oligo GEArray (SABiosciences).  Analysis was performed using the GEArray 
Expression Analysis Suite software (SABiosciences). 
2.3.7.  Real-time PCR 
Real-time one-step RT-PCR was performed on total RNA via an Eppendorf Mastercycler 
ep Realplex2 (Eppendorf, Westbury, NY) using QuantiTect Primers optimized for 
QuantiTect SYBR Green RT-PCR kit (Qiagen, Valencia, CA).  Results were normalized 
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to β-actin, which was chosen over gapdh and β2M as the housekeeping gene, since it was 
least affected by treatment.  Data was analyzed by ∆∆Ct calculations. 
2.4.  Results 
2.4.1.  Tumor lysate matures iDCs 
Overnight incubation of iDC with B16F0 tumor cell lysate induced DC 
maturation with respect to inflammatory chemokine and chemokine receptors.  iDCs 
express high levels of inflammatory receptors: CCR2 and CCR5 and low levels of 
inflammatory chemokines: CCL3, CCL5 and CCL22.  Upon antigen uptake and 
processing, iDCs are induced to decrease levels of inflammatory receptors, while 
increasing inflammatory chemokine expression.  Microarray analysis shows tumor lysate 
pulsed iDCs (LPiDCs) displayed a drastic reduction in ccr2 and ccr5 and an increase in 
inflammatory and inducible chemokines ccl3, ccl5 and ccl22; their levels were nearly 
identical to DCs matured with LPS (Figure 2.1A).  
DCs cultured from C57BL/6J mice were matured with LPS on day 8 of culture.  
On day 10, they were incubated with B16F0 tumor lysate and RNA was extracted after 
overnight incubation.  RNA microarray shows that tumor lysate pulsing of mDCs 
(LPmDC) caused no change in expression of ccr2, ccr5, ccl3, ccl5, or ccl22 compared to 




Figure 2.1:  Tumor lysate pulsing matures iDC, but causes no change in mDC   
Total RNA was extracted from iDC, LPiDC, mDC, and LPmDC and was analyzed by 
RNA microarray for the indicated chemokine and chemokine receptors.  (A) Gene 
expression profiles of LPiDC and mDC compared to iDC.  (B) Gene expression profiles 




2.4.2.  Fusion with tumor cells matures iDC 
iDCs were fused with B16F0 tumor cells by PEG in a 2:1 ratio.  The fused 
hybrids (immature dendritomas or iDT) were purified from the fusion mixture by dual 
fluorescent FACS sorting on day 11.  RNA was extracted from iDTs following collecti n 
and used for RNA microarray.  As shown in Figure 2.2A, iDTs dramatically decreased 
expression of ccr2 and ccr5, but increased ccl3, ccl5 and ccl22 as compared to iDCs.  
This pattern is consistent with the expression of mDCs and LPiDCs (Figure 2.1A);
therefore, fusion of iDC with tumor cells instigates maturation with respect to these 
inflammatory chemokines and receptors.  To further confirm this finding, real-time RT-
PCR was performed to measure the change of expression in ccr2, ccr5, ccl3, ccl5, and 
ccl22 in iDTs.  The results, as shown in Figure 2.2B, demonstrate a similar pattern of 
expression: down-regulation of ccr genes and up-regulation of ccl genes.   
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Figure 2.2:  Fusion with tumor cells matures dendritic cells.  iDCs were fused with 
C1498 or B16F0 tumor cells in a 1:1 or 2:1 ratio using PEG in two separate experiments.  
The fusion hybrids (iDT) were generated by FACS sorting based on the DT technology 
(see Materials and Methods).  Total RNA was analyzed by RNA microarray nd real-
time RT-PCR for the indicated genes.  (A) Microarray analysis of chemokine and 
chemokine receptor gene expression by iDTs, iDC = 1.  (B) Real-time RT-PCR analysis 
of chemokine and chemokine receptor gene expression by iDTs, iDC = 1.  (*p<0.05, 





Additional genes associated with LPS induced DC maturation were examined in 
two independent microarray experiments in iDTs made from either C1498 tumor cells or 
B16F0 tumor cells.  As shown in Figure 2.3, acpp, atf4, clec4d, ifit1, il-1b, g1p2, and 
prg1 were upregulated (Figure 2.3A), while cd209a, f13a1, icosl, ifi30, ifngr1, rnase6, 
and s100a4 were downregulated (Figure 2.3B), indicating that fusion of iDCs and tumor 
cells yields a maturing hybridoma. 
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Figure 2.3:  Fusion of iDCs with tumor cells yields a similar gene profile to LPS 
matured DCs.  iDCs were fused with C1498 or B16F0 tumor cells in a 1:1 or 2:1 ratio 
using PEG in two separate experiments.  The fusion hybrids (iDT) were generated by 
FACS sorting based on the DT technology (see Materials and Methods).  Total RNA was 
analyzed by RNA microarray for the indicated genes.  (A) Genes upregulated by both 
iDTs and LPS matured DCs compared to iDCs.  (B) Genes downregulated by iDTs and 
LPS matured DCs compared to iDCs.  
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2.4.3.  Fusion with tumor cells reverses the maturation for mDTs 
DCs cultured for 8 days were matured with LPS for two days and fused with 
B16F0 tumor cells.  The hybrids (mature dendritomas or mDT) were purified from the 
fusion mixture using the same technology described above.  RNA microarray established 
the increased expression of ccr2 and ccr5, while the expression of ccl3, ccl5, and ccl22 
decreased (Figure 2.4A): a clear pattern of DC de-maturation with respect to 
inflammatory ccl and ccr.  This finding is in contrast to lysate pulsed mDCs where no 
significant change was observed (Figure 2.1B).  Real-time RT-PCR also confirmed the 
change of expression in ccr2, ccr5, ccl3, ccl5, and ccl22 in mDTs.  The results, shown in 
Figure 2.4B, are consistent with microarray data: ccr genes are upregulated and ccl genes 
downregulated.  Additional genes of interest analyzed by microarray of mDTs showed a 
similar pattern compared to iDCs.  Cd209a, f13a1, marcks, rpl13a, cd207, cdc42, and 
pfn1 were upregulated (Figure 2.5A), while acpp, atf4, clec4d, il-1b, il-12b, cd36, sod2, 
cd80, pnrc1 and tnfsf4 were downregulated (Figures 2.5B), further supporting de-
maturation of mDTs. 
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Figure 2.4:  Fusion of mDCs with tumor cells (mDT) yields an opposing 
chemokine/chemokine receptor pattern to mature DCs.  mDCs were fused with 
B16F0 tumor cells in a 2:1 ratio using PEG.  The fusion hybrids, mDT, were generated 
by FACS sorting based on the DT technology (see Materials and Methods).  Total RNA 
was analyzed by RNA microarray and real-time RT-PCR for the indicated genes.  (A) 
Microarray analysis of chemokine and chemokine receptor gene expression by mDTs, 
mDC = 1.  (B) Real-time RT-PCR analysis of chemokine and chemokine receptor gene 




Figure 2.5:  Fusion of mDCs with tumor cells de-matures mDTs.  mDCs were fused 
with B16F0 tumor cells in a 2:1 ratio using PEG.  The fusion hybrids, mDT, were 
generated by FACS sorting based on the DT technology (see Materials and Methods).  
Total RNA was analyzed by RNA microarray for the indicated genes.  (A) Genes 
upregulated by both mDTs and iDCs compared to mDCs.  (B) Genes downregulated by 
mDTs and iDCs compared to mDCs.  
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2.5.  Discussion 
Tumor lysate pulsed immature DCs (LPiDCs) are mature compared to iDCs.  
LPiDCs express increased levels of CD80, CD86, and CD40 costimulatory molecules as 
well as molecules involved in antigen presentation while decreasing those involved with 
antigen uptake (Paglia et al., 1996; Berard et al., 2000).  For the first time, we show that 
LPiDCs are activated to elevate ccl levels and decrease ccr levels (Figure 2.1A), 
suggesting that antigen-pulsing results in efficient DC activation to mediate the 
chemokine receptor paradigm switch in the absence of other inflammatory stimuli or 
microbial products such as LPS. 
We did not observe any significant change in the genes analyzed by microarray 
for tumor lysate pulsed, LPS matured DCs (LPmDCs, Figure 2.1B).  This could be due to 
the notion that LPS matured DCs have downregulated antigen-uptake mechanisms, or 
compared to microbial danger signals, tumor lysates are weak DC maturation agents.  
Interestingly, it has been shown that coincubating mDCs with CCR7 ligands, 
CCL19/ELC or CCL21/SLC, re-stimulates endocytosis by previously matured DCs 
(Yanagawa et al., 2003); therefore, it seems plausible to induce mDC uptake of tumor 
lysate by concomitant incubation with a CCR7 ligand.  Based on our data, it would be 
better to use iDCs to engage tumor antigens; nonetheless, it would be interesting to 
observe the effects of pulsing mDCs with tumor lysate combined with ELC or SLC. 
iDTs, composed of tumor cells and iDCs, express increased levels of cc  genes 
and decreased ccr genes (Figure 2.2).  This process is assumed to be mostly due to the 
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autocrine action of chemokines on their respective receptors expressed by DCs (Kikuchi 
et al., 2001; Sozzani et al., 1998); although it has been shown that C5a and fMPL do not 
have this autodesensitization effect on DCs (Sozzani et al., 2000).  In addition to the ccl 
and ccr paradigm switch, iDT maturation is also accompanied with up-regulation of 
genes such as acpp, atf4, clec4d, ifit1, il-1b, g1p2, and prg1 and down-regulation of 
cd209a, f13a1, icosl, ifi30, ifngr1, rnase6, and s100a4 as confirmed in two separate 
microarray analyses and also observed in canonical DC maturation when iDCs are 
matured with LPS (Figure 2.3).  Again, our data points to successful maturation when 
iDCs are fused to tumor cells (iDTs) which is important when designing DC vaccines.  
Interestingly, we observed that iDTs expressed high levels of i -10 in two separate 
microarrays, while mDTs expressed non-detectable levels of il-10 (data not shown), 
contradicting other reports where both iDC/tumor fusions and mDC/tumor fusions have 
elevated levels of IL-10 (Vasir et al., 2008).  This may implicate the need for 
simultaneous addition of a danger signal to overcome IL-10 production when 
manufacturing iDTs.  More studies are needed to clarify the role of IL-10 in this process. 
Mature DCs used for fusion oddly de-mature, whereas iDCs are matured with 
fusion to tumor cells.  Interestingly, the ccl and ccr expression of mDTs was completely 
reversed compared to iDTs and mDCs.  There was a significant decrease in ccl 
expression with a compensating increase in ccr expression (Figure 2.4), closely 
mimicking the ccr and ccl expression of iDCs.  This phenomenon may be due to 
complete washing of mDCs before fusion, which frees the supernatant of CCLs, no 
longer triggering autodesensitization.  Taking this into account, mDTs may not be as 
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good as iDTs for migration from injection sites to draining lymph nodes.  Not only did 
mDTs de-mature with respect to ccr and ccl expression, but they also upregulated 
cd209a, f13a1, marcks, rpl13a, cd207, cdc42, and pfn1, and downregulated acpp, atf4, 
clec4d, il-1b, il-12b, cd36, sod2, cd80, pnrc1 and tnfsf4 (Figure 2.5) in synchrony with 
iDCs.  Our data suggest mDTs may need restimulation with CCLs or possibly other 
danger signals in order to resume proper migratory capacity and antigen presentation 
since they seem to have more genes in common with iDCs than mDCs.  It is possible that 
stimulating dendritomas with microbial danger signals or adjuvants could overcome this 
problem as seen with pre-treatment and post-treatment with OK432 and CpG ODN 
increasing the effectiveness of DC fusion vaccines (Li et al., 2008; Koido et al., 2007a; 
Koido et al., 2007b). 
In conclusion, our data unfolds a significant pattern of chemokine expression in 
dendritomas depending on the maturation state of DCs and demonstrates the plasticity of 
LPS matured DCs used for vaccine preparation.  Although mature DCs are preferred to 
reduce tolerance or expansion of regulatory cells, we see here there may bproblems 
with migration and induction of immune response.  To circumvent this problem, either 
immature DCs should be used for fusion with simultaneous addition of a danger signal 
such as LPS, OK432, or CpG ODN to properly mature the DCs and abrogate production 
of IL-10; or if mature DCs are used for fusion, it must be investigated to see if they can 
be re-stimulated to secrete CCLs, down-regulate CCRs, and reclaim maturation in order 
to properly migrate and activate an immune response against presented tumor antigens. 
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3. MORINDA CITRIFOLIA (NONI) AS AN IMMUNOMODULATOR 
OF DENDRITIC CELLS: INHIBITION OF TOLL-LIKE 
RECEPTOR AND NFκB PATHWAYS AND PROCUREMENT OF 
ANTI-INFMMATORY MEDIATORS 
 
3.1.  Abstract 
 
Morinda citrifolia (Noni) has been used for centuries to treat a wide range of 
maladies.  Its current growth as a dietary supplement to enhance the immune system has 
demanded more scientific research into its purported effects.  Whereas most previous 
reports have been self-published, recent information has been described in peer-reviewed 
scientific journals on the anticancer, anti-inflammatory, and immunomodulatory effects 
of Noni.  Also, fermented Noni exudate was shown to activate dendritic cells, one of the 
key players in innate and adaptive immunity.  Noni fruit contains a wide variety of 
microorganisms, and upon fermentation all but one are killed, resulting in a large array of 
pathogen-associated molecular patterns (PAMPs), potentially activating pattern-
recognition receptors.  Since dendritic cells express a wide variety of Toll-like receptors 
(TLRs), we hypothesized that Noni-treated dendritic cells would alter the expression of 
inflammatory genes downstream of TLR pathways.  The expression of tnf, il-6, ptgs2, 
ccl3 and ccl5 were examined in Noni-stimulated bone marrow-derived dendritic cells.  
Furthermore, in a second experiment, dendritic cells were treated with endotoxi -
depleted Noni and 84 genes in the TLR pathway were evaluated.  Both experiments wer 
carried out by real-time RT-PCR with SYBR green chemistry.  FACS analysis also 
revealed an intriguing shift from a CD11c+CD83+ dendritic cell population to a much 
larger Mac-3+ population.  Overall, Noni induced low levels of inflammatory cytokines, 
significantly increased anti-inflammatory mediators, and inhibited elements of TLR 
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signaling, specifically NFκB.  Gradually, Noni’s molecular mechanisms of action on 
immune cells are being unraveled, and will hopefully clarify its antitumor and anti-
inflammatory roles for possible drug development. 
3.2.  Introduction 
Morinda citrifolia, commonly known as Noni in the US and Hawaii, is 
widespread throughout Polynesia, Southeast Asia, India, and Australia. It was brought to 
the Pacific Islands more than 2000 years ago as the ancient Polynesians second most 
popular medicinal herb. Cultures throughout the region have, for millennia, employed 
every part of the plant as a food staple and for an immense range of illnesses and 
ailments, including bacterial and viral infection, fungus, cancer, AIDS, high blood 
pressure, and much more. In all, there are 40 known and recorded uses for the plant in 
herbal remedies.  In addition, the leaves of the plant have been used to produce dyes for 
clothing and other textiles (Wang, 2004; Pawlus et al., 2007).  
Noni grows as a small evergreen tree. It reaches 12-15 feet in height, is decorated 
with large bright green elliptical leaves, columnar white flowers and lumpy yellow fruit, 
about the size of a potato. Its seeds have an air sac at one end, giving them the buoyancy 
they need to float across the pacific and take root in islands throughout the region, to ear  
the name “ocean-going Noni,” as the plant has been called in some regions. Finally, the 
Noni fruit can be identified by its rancid odor and foul taste – justifying another popular 
name – the “cheese fruit” (Dixon et al., 1999; Wang et al., 2002) 
Extensive research is ongoing to identify both known and novel active 
compounds of Noni.  These include, but are not limited to, novel anthraquinones, 
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saccharide fatty acid esters, glycosides, iridoid glucosides and damnacanthal (Akihisa et 
al., 2007; Guangming et al., 2001; Su et al., 2005; Hiwasu et al., 1999; and Kamata et
al., 2006).  Currently, several potent antioxidants and anti-inflammatory agents have been 
extracted and identified (Pawlus et al., 2007; Deng et al., 2007; Pawlus et al., 2005; 
Ikeda et al., 2009; Su et al., 2005).  Besides isolated compounds, different fractions of 
Noni have been studied for immunomodulatory effects.  A polysaccharide-rich 
precipitate of Noni juice has been found to have antitumor potential (Hirazumi et al., 
1999; Furusawa et al., 2003).  Raw Noni, or Noni puree, shows antiangiogenic, cancer 
preventive and bactericidal properties (Wang et al., 2001; Wang et al., 2002; Wang et al., 
2008; Hornick et al., 2003; Palu et al., 2007; Schafer et al., 2008).  Wong reported two 
case studies involving patients with adenocarcinoma self medicating with fermented 
Noni.  The first patient began drinking Noni on his deathbed after refusing medical 
treatment, and showed no evidence of disease a year after diagnosis. The second patient, 
who underwent surgery and had metastases in 17 of 28 lymph nodes tested, survived 
sixteen years disease-free with the Noni treatment (Wong et al., 2004). This is extremely 
significant since less than ten percent of patients survive even five years with this level of 
metastasis. 
Recently, our lab has examined the immunomodulatory effects of fermented Noni 
exudate (fNE) in animal models.  It was found that dendritic cells (DCs) cultured with 
fNE are capable of inducing B cell proliferation, differentiation and even Ig class 
switching (Zhang et al., 2009).  Furthermore, fNE was found to be effective for both 
prevention and treatment of mice with S180 sarcomas and Lewis Lung carcinomas (Li et 
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al., 2008; Furusawa et al., 2003). These studies clearly demonstrated that both the innate 
and adaptive immune systems are involved in the antitumor effect induced by fNE.   
Although fresh Noni fruit has a myriad of microflora, upon fermentation, only one 
fungus remains in fNE (personal communication, Marisa Wall, 2009).  Our lab also 
found that fNE contains detectable levels of endotoxin (unpublished data).  It was 
speculated that this novel strain of fungi along with endotoxin in fNE may be responsible 
for activating several innate pattern recognition receptors (PRRs), which could be 
responsible for its anti-inflammatory, anticancer and other immune-modulating 
properties.  In this study, we tested DCs treated with fNE, endotoxin-removed fNE (E-
fNE), or LPS for expression of genes involved with PRR signaling via real-time PCR.  
We show for the first time that fermented Noni, the most popular traditional method of 
Noni consumption, increases several inflammatory mediators at suppressed levels 
compared to LPS, but upon endotoxin removal, clearly promotes an anti-inflammatory 
response from DCs. 
3.3.  Materials and Methods 
3.3.1.  Animals 
Female C57BL/6J mice, 6-8 weeks of age, were purchased from Jackson 
Laboratories (Bar Harbor, ME) and housed in our pathogen-free animal facilities.  
Animal experiments were carried out in accordance with both Guidelines for the Care 
and Use of Laboratory Animals (NIH Publication number 85-23) and institutional 
guidelines. 
3.3.2.  Dendritic Cells 
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Bone marrow-derived DCs were cultured as previously described (Lutz et al., 
1999).  Briefly, bone marrow cells flushed from C57BL/6J mouse femurs and tibiae with 
RPMI-1640 (Gibco BRL) were filtered through 40-µm nylon cell strainers. After lysing 
of RBCs with ACK lysing solution, the  cell pellet was resuspended in DC medium 
containing RPMI-1640 (Gibco BRL) supplemented with 10% FBS (Hyclone), 50 µg/ml 
gentamicin (Gibco BRL), and 20 ng/ml rmGM-CSF (Sigma, St. Louis, MO) and plated at 
a density of 4-5x106 cells/10 ml in a 100-mm tissue culture dish.  On day 4, 10 ml fresh 
DC media was added to each dish.  On day 8, nonadherent and loosely adherent cells 
were harvested, washed with RPMI-1640 and replated into 6-well plates with fresh DC 
medium containing 10 ng/ml rmGM-CSF.  These DC cultures were stimulated overnight 
with either filtered fNE supernatant at 1, 5 or 10% or LPS at 2.5, 12.5, 25 or 100ng/ml 
prior to RNA extraction. 
3.3.3.  Production of Fermented Noni Exudate (fNE) 
Production of fNE was previously reported (Zhang et al., 2009).  Briefly, ripe 
Noni (Morinda citrifolia) fruits were harvested from Kawaihae, Hawaii, thoroughly 
cleaned and placed in sterilized containers for fermentation at 24-30°C and humidity 
between 45-55%.  Fermentation was terminated at 14 days and the seepage was collected
in plastic bottles and stored at -80°C prior to its use.   Before incubation with DCs, the 
liquid fermented Noni exudate (fNE) was pH adjusted to 7.0-7.4 with 50% NaOH, 
centrifuged to discard debris and sterilized by passing through a 0.22µm syringe filter.  
Endotoxin removal of Noni was performed by Detoxi-Gel™ Endotoxin Removing Gel 
(Thermo Scientific) according to manufacturer’s instructions.  Briefly, Detoxi-Gel 
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columns were regenerated with 1% sodium deoxycholate, then washed with pyrogen-free 
DPBS (Lonza) prior to fNE loading.  Once fNE was loaded onto the column, it was 
allowed to sit at room temperature for one hour before washing through with an equal 
amount of DPBS.  The endotoxin-depleted fNE flow-through was collected, passed 
through a 0.22µm filter, and used immediately in cell cultures.  
3.3.4.  Real-Time RT-PCR 
Purified total RNA was isolated from stimulated or non-stimulated DCs using the 
RNeasy Plus Kit (Qiagen) according to the manufacturer’s protocol and reverse 
transcribed with QuantiTect Reverse Transcription Kit (Qiagen).  Nucleic acids were 
quantified using a Qubit fluorometer and appropriate Quant-it Assay Kits (Invitrogen).  
cDNA was analyzed for the expression of Tlr4, Tnf, Il-6, Ptgs2, Ccl3 and Ccl5 by SYBR 
green chemistry real-time PCR using the QuantiTect SYBR Green Kit (Qiagen).  Real-
time RT-PCR was carried out on the Mastercycler ep Realplex2 (Eppendorf) with PCR 
cycles recommended by the primer sets.  Primer sequences were purchased from Real 
Time Primers, LLC and their sequences are available online at 
www.realtimeprimers.com. 
3.3.5.  PCR Array 
Purified total RNA was isolated as described above for use in the PCR arrays; 
however, it was reverse-transcribed with RT2 First-Strand cDNA Synthesis Kit 
(SABiosciences).  Manufacturer’s instructions were followed for running the PCRarray; 
briefly, cDNA templates were mixed with the provided PCR master mix and were 
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aliquoted into all 96-wells of the Toll-like Receptor Signaling Pathway PCRarray 
(SABiosciences).  The PCR cycling program was set according to the PCRarray protocol. 
3.3.6.  Statistical Analysis 
Fold change in gene expression for real-time RT-PCR data was calculated using 
the Pfaffl method, taking into account varying primer efficiencies.  Statistical analyses of 
data were performed by analysis of variance (ANOVA) followed by Bartlett’s test using 
Graph Pad Prism® 4 software.  PCR arrays were analyzed with the complimentary RT2 
Profiler TM PCR Array Data Analysis (SABiosciences) which determines ∆∆Ct 
calculations normalized to at least 3-5 housekeeping genes, with pair-wise comparison 
between treated and untreated samples.  
3.4.  Results 
3.4.1.  Real-time RT-PCR 
Immature DCs (iDCs) were treated with fNE or E-fNE at 1%, 5% or 10% total 
media concentration, or LPS at 2.5ng/ml, 12.5ng/ml and 25ng/ml for 2, 24, 48 or 72h.  
LPS concentrations were calculated to be equivalent to endotoxin levels of fNE.  Total 
RNA was extracted and the expression of Tlr4 and five downstream genes of the TLR4 
pathway were assessed by real-time RT-PCR using ∆∆Ct method of analysis. 
3.4.1.1.  Toll-like receptor 4 (tlr4) 
fNE did not affect tlr4 gene expression after 2h treatment.  At 24 and 48 hours, 
5% fNE significantly decreased tlr4, while surprisingly, 10% fNE did not change the 
gene expression in these time periods.  After 72h treatment, a clear dose-dependent 
down-regulation of tlr4 was observed (Figure 3.1A).  Since fNE contains LPS (our un-
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published data), we also tested the effect of LPS on tlr4 expression by DCs.  LPS in 
concentrations equivalent to the amount measured in fNE was used.  LPS had no effect 
on tlr4 at 2, 48 or 72h.  Only at 24h was tlr4 expression significantly downregulated by 
12.5 and 25 ng/mL LPS, respectively (Figure 3.1B). Furthermore, since the down-
regulation of tlr4 gene expression induced by fNE was not completely repeated by LPS 
treatment, we tested the effect of endotoxin-removed fNE, or E-fNE, on iDCs.  After 24 
hours treatment, both 1% and 5% E-fNE significantly downregulated tlr4, while at other 
time points (2h, 48, or 72h), there was no effect (Figure 3.1C). These data suggest the 


















































































































































Figure 3.1.  tlr4 expression by Noni- or endotoxin-depleted Noni-treated BMDCs 
compared to LPS treated BMDCs.  BMDCs were treated for 2, 24, 48 or 72h with Noni 
or endotoxin-depleted Noi at 1%, 5%, or 10% total media concentrations or with 
corresponding levels of endotoxin (2.5-, 12.5-, or 25ng/ml LPS).  Real-time RT-PCR was 
performed on cDNA from the resulting samples.  (A) fNE treatment of BMDCs; (B) LPS 
treatment of BMDCs; (C) E-fNE treatment of BMDCs.  Experiments were p rfomed in 
triplicate and data was analyzed by ANOVA followed by Bartlett’s post-test. * p<0.05   




3.4.1.2. Tumor necrosis factor-alpha (tnf) 
DCs treated with fNE induced a dose-dependent increase of tnf gene expression at 
2h, while at 24h and 48h, only 10% fNE caused a significant increase.  At 72h, all three 
concentrations induced a significant, albeit small, increase (Figure 3.2A). Similarly, LPS 
treatment of DCs caused a strong, non-dose dependent increase in tnf at 2h.  At 24h, only 
25ng/mL LPS significantly altered the expression of tnf; and by 72h there was no 
significant change (Figure 3.2B).  E-fNE treatment of DCs, on the other hand, induced a 
dose-dependent decrease in tnf expression at 2h.  While 24h and 48h incubations did not 
cause a significant change, 72h treatment induced a very significant 6.6-fold decrease in 
tnf (Figure 3.2C).  The increase in tnf by fNE-treated DCs seems to be attributed to the 
endotoxin in Noni, since upon endotoxin removal, not only is tnf production abrogated, 
but it is actually dose-dependently decreased.  This fraction of Noni responsible for 
decreasing tnf is also observed in fNE-treated DCs since 5% fNE treatment only caused a 
14-fold increase and equivalent endotoxin concentrations (12.5ng/mL LPS) induced 125-





































































































































Figure 3.2:  tnf expression by Noni- or endotoxin-depleted Noni-treated BMDCs 
compared to LPS treated BMDCs.  BMDCs were treated for 2, 24, 48 or 72h with Noni 
or endotoxin-depleted Noi at 1%, 5%, or 10% total media concentrations or with 
corresponding levels of endotoxin (2.5-, 12.5-, or 25ng/ml LPS).  Real-time RT-PCR was 
performed on cDNA from the resulting samples.  (A) fNE treatment of BMDCs; (B) LPS 
treatment of BMDCs; (C) E-fNE treatment of BMDCs.  Experiments were p rfomed in 
triplicate and data was analyzed by ANOVA followed by Bartlett’s post-test. * p<0.05   
** p<0.01   *** p<0.001  
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3.4.1.3.  Interleukin-6 (il-6) 
fNE treatment caused a dose-dependent increase in il-6 production by iDCs at 2h; 
however, only 10% fNE remained effective through 72h, where its production peaked at 
48h, 633.8-fold higher than untreated DCs (Figure 3.3A).  LPS treatment also caused a 
non dose-dependent increase at 2h, where it peaked at 985.3-fold greater than the control.  
Lower dose-dependent responses were noted at 24h and 48h, with a drastic latent rebound 
at 72h where 12.5 and 25 ng/mL LPS treatment increased il-6 expression 717- and 731-
fold above untreated DCs (Figure 3.3B).  E-fNE completely abolished the up-regulation 
of il-6 induced by fNE.  Furthermore, a very significant down-regulation of il-6 occurred 
for 1% E-fNE, dropping 47-fold (Figure 3.3C). fNE significantly increased il-6 
expression in DCs, although not as high as LPS.  Upon endotoxin removal, E-fNE 
ultimately decreases production of il-6 at 72h.  Again, endotoxin seems to be responsible 























































































































































Figure 3.3:  il-6 expression by Noni- or endotoxin-depleted Noni-treated BMDCs 
compared to LPS treated BMDCs.  BMDCs were treated for 2, 24, 48 or 72h with Noni 
or endotoxin-depleted Noi at 1%, 5%, or 10% total media concentrations or with 
corresponding levels of endotoxin (2.5-, 12.5-, or 25ng/ml LPS).  Real-time RT-PCR was 
performed on cDNA from the resulting samples.  (A) fNE treatment of BMDCs; (B) LPS 
treatment of BMDCs; (C) E-fNE treatment of BMDCs.  Experiments were p rfomed in 
triplicate and data was analyzed by ANOVA followed by Bartlett’s post-test. * p<0.05   
** p<0.01   *** p<0.001  
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3.4.1.4.  Prostaglandin-endoperoxide synthase 2 (Ptgs2) 
Treatment of iDCs with fNE caused a dose-dependent increase in ptgs2 at 2h, 
followed by a sustained up-regulation through 48h by 10% fNE. Although a lower fold 
increase, 5% and 10% fNE significantly upregulated Ptgs2 expression at 72h (Figure 
3.4A).  LPS treatment also caused a dose-dependent increase at 2h, followed by an 854-
fold peak at 24h.  Levels decreased by 48h, but remained dose-dependently upregulated.  
Surprisingly, at 72h 2.5 ng/mL and 25 ng/mL LPS treatments upregulated ptgs2 635- and 
584-fold, respectively, while 12.5ng/ml LPS did not show any effect.  Of interest, at 2h 
the upper level of concentrations for both fNE and LPS treatments induced a nearly 
identical up-regluation of ptgs2 at 453- and 445-fold, correspondingly (Figure 3.4B).  E-
fNE induced a much smaller scale up-regulation of ptgs2, peaking at merely 15.2-fold 
above the DC control.  At 72h, it began to down-regulate expression, where 1% E-fNE 
decreased ptgs2 19-fold (Figure 3.4C).  It is likely that some other component of fNE is 
responsible for up-regulating the production of ptgs2, since upon endotoxin removal, 2h 




































































































































































Figure 3.4:  ptgs2 expression by Noni- or endotoxin-depleted Noni-treated BMDCs 
compared to LPS treated BMDCs.  BMDCs were treated for 2, 24, 48 or 72h with Noni 
or endotoxin-depleted Noi at 1%, 5%, or 10% total media concentrations or with 
corresponding levels of endotoxin (2.5-, 12.5-, or 25ng/ml LPS).  Real-time RT-PCR was 
performed on cDNA from the resulting samples.  (A) fNE treatment of BMDCs; (B) LPS 
treatment of BMDCs; (C) E-fNE treatment of BMDCs.  Experiments were p rfomed in 
triplicate and data was analyzed by ANOVA followed by Bartlett’s post-test. * p<0.05   
** p<0.01   *** p<0.001  
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3.4.1.5.  Chemokine ligand-3 (Ccl3) 
At 2h, ccl3 expression peaked with 5% fNE treatment.  At 24h, 1% and 5% fNE 
did not significantly alter its expression, but 10% fNE induced the highest level of ccl3 at 
8.13-fold above control.  By 48h, 1% and 5% fNE significantly downregulated ccl3 
(Figure 3.5A).  LPS induced stronger ccl3 expression at 2h than fNE, peaking at 26-fold 
above control for 12.5 ng/mL; however, no significant change occurred from 24-72h 
(Figure 3.5B).  E-fNE abolished the effects of ccl3 up-regulation by fNE and strongly 
downregulated its expression at 72h, where 1% E-fNE decreased ccl3 expression as low 
as 27.5-fold below control (Figure 3.5C). Overall, fNE and LPS treatment quickly 
increased expression of ccl3 in DCs, but this effect tapered off with time.  Upon removal 
of endotoxin, E-fNE caused no significant change in ccl3 expression from 2-48h, but a 
strong 27.5-fold down-regulation at 72h.  Endotoxin appears responsible for  ccl3 













































































































































































Figure 3.5:  ccl3 expression by Noni- or endotoxin-depleted Noni-treated BMDCs 
compared to LPS treated BMDCs.  BMDCs were treated for 2, 24, 48 or 72h with Noni 
or endotoxin-depleted Noi at 1%, 5%, or 10% total media concentrations or with 
corresponding levels of endotoxin (2.5-, 12.5-, or 25ng/ml LPS).  Real-time RT-PCR was 
performed on cDNA from the resulting samples.  (A) fNE treatment of BMDCs; (B) LPS 
treatment of BMDCs; (C) E-fNE treatment of BMDCs.  Experiments were p rfomed in 
triplicate and data was analyzed by ANOVA followed by Bartlett’s post-test. * p<0.05   
** p<0.01   *** p<0.001  
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3.4.1.6.  Chemokine ligand-5 (Ccl5) 
fNE treatment caused no significant change in ccl5 production at 2h, but a dose-
dependent increase was observed at 24h, 48h and 72h.  Its production peaked at 72h for 
10% fNE, where it was 62.5-fold higher than untreated DCs (Figure 3.6A).  LPS at 
12.5ng/ml and 25ng/ml induced minimal expression of ccl5 at 2h, then a much greater 
expression from 24-72h, peaking at 78.4-fold at 24h.  Ccl3 production remained 
increased at relatively consistent levels for all concentrations of LPS from 24-72h (Figure 
3.6B).  E-fNE caused no significant change in ccl3 expression from 2-48h, but again, 
induced down-regulation of the gene at 72h, where 1% E-fNE caused a 19.7-fold 












































































































































































Figure 3.6:  ccl5 expression by Noni- or endotoxin-depleted Noni-treated BMDCs 
compared to LPS treated BMDCs.  BMDCs were treated for 2, 24, 48 or 72h with Noni 
or endotoxin-depleted Noi at 1%, 5%, or 10% total media concentrations or with 
corresponding levels of endotoxin (2.5-, 12.5-, or 25ng/ml LPS).  Real-time RT-PCR was 
performed on cDNA from the resulting samples.  (A) fNE treatment of BMDCs; (B) LPS 
treatment of BMDCs; (C) E-fNE treatment of BMDCs.  Experiments were p rfomed in 
triplicate and data was analyzed by ANOVA followed by Bartlett’s post-test. * p<0.05   
** p<0.01   *** p<0.001  
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3.4.2.  RT-PCR Array 
Based on the greater suppressive nature of E-fNE, we decided to further examine 
some other genes involved in signaling pathways and adaptor molecules affected by E-
fNE.  We performed real-time PCR array on 84 genes involved in TLR signaling and 
several downstream pathways (NFκB, JNK, IRF, etc).  iDCs were incubated with 5% E-
fNE for 2, 24 or 48h; total RNA was extracted, and real-time RT-PCR was perform d to 
assess the regulation of genes related to TLR signaling.  Upregulated and dow regulated 




Table 3.1:  Upregulated genes of the 
TLR signaling pathway by Noni 
treated DCs.  Non-stimulated BMDCs 
were treated with 5% endotoxin-
removed fermented Noni exudate (E-
fNE) for 2, 24 or 48h.  Total RNA was 
extracted and real-time RT-PCR was 
performed on the 84 genes of the TLR 
pathway PCRarray from 
SABiosciences.  Arrays were 
normalized to at least 2-5 
housekeeping genes and compared to 
non-treated BMDCs.  Triplitate 
PCRarrays were performed on 2h and 
24h samples.  Only one PCRarray was 
performed on the 48h E-fNE sample 
and one on the 48h non-treated DC 
control.  The delta-delta Ct method 













  Upregulated Genes (Fold Regulation) 
Gene 2 hour p 24 hour p 48 hour 
Tlr2 2.7 ***       
Tlr5 2.3 *       
Cd14 1.7 **       
Hspa1a 2.1 ** 32.8 *** 560.3 
Mapk8ip3 1.7 *       
Peli1 2.7 ***       
Ripk2 2.3 *       
Tollip     1.6 **   
Traf6 2.6 *       
Ifnβ1 10.5 *** 157.8 *** 1596 
Il-1a 16.6 ***       
Il-1b 28.3 ***       
Il-6 41.9 *** 36.8 *** 47.2 
Il-10 18.7 *** 15.7 *** 1.6 
Nfkb1 2 **       
Nfkb2 1.8 ***       
Nfkbia 3.2 ***     2.7 
Nfkbib      1.8 *   
Nfkbil1  3.1 ***       
Rel 4.7 *** 2.3 *   
Tnfaip3 5.3 **     4 
Jun 1.5 * 2     
Mapk8  1.8 *       
Cebpb     2     
Clec4e 3.4 **       
Ptgs2 83 *** 267.8 *** 2.4 
Cxcl10 15.8 *** 6 * 47.2 
Ifnβ1 10.5 *** 157.8 *** 1596 
Irf1 2.3 **       
Irf3 1.9 **     2.3 
Tbk1 1.7         
Cd80 2.5 ** 2.5 * 6.6 
Cd86     3.7 ** 3.3 
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Table 3.2:  Downregulated genes of 
the TLR signaling pathway by Noni 
treated DCs.  Non-stimulated BMDCs 
were treated with 5% endotoxin-
removed fermented Noni exudate (E-
fNE) for 2, 24 or 48h.  Total RNA was 
extracted and real-time RT-PCR was 
performed on the 84 genes of the TLR 
pathway PCRarray from 
SABiosciences.  Arrays were 
normalized to at least 2-5 
housekeeping genes and compared to 
non-treated BMDCs.  Triplicate 
PCRarrays were performed on 2h and 
24h samples.  Only one PCRarray was 
performed on the 48h E-fNE sample 
and one on the 48h non-treated DC 
control.  The delta-delta Ct method 
was used to calculate fold change in 
gene expression.   Fold regulation 













  Downregulated Genes (Fold Regulation) 
Gene 2 hour p 24 hour p 48 hour 
Tlr1     -2.6 * -2.3 
Tlr2     -4.2 *** -15.2 
Tlr4     -5.3 **   
Tlr5         -10.6 
Tlr7     -8.6 * -4.2 
Tlr8     -299 *** -228 
Tlr9     -5.5 ** -6.7 
Btk     -6.0 *** -5.3 
Cd14         -9.1 
Ly86     -22.8 *** -18.6 
Ly96         -3.4 
Myd88     -5.2 *** -9.5 
Peli1         -2.4 
Ticam2     -3 ** -6.5 
Tirap -2.4 *     -13.9 
Casp8     -3.8 *** -10.3 
Fadd     -3.1 ** -7.4 
Irak1     -9.6 * -3.5 
Map3k7     -2.9 *** -4.3 
Ube2n     -6.9 ***   
Ube2v1     -2.3 **   
Ccl2     -2.2 *** -38.3 
Ikbkb     -4.2 ** -10.6 
Il-1a         -10.8 
Il-1b         -76.6 
Il-1r1     -4.6 ** -8.9 
Map3k1     -2.7 *   
Rela     -10.3 *   
Tnf     -15.4 *   
Tnfrsf1a     -3.5 ** -3.4 
Elk1     -2.4 *   
Fos     -5.9 ** -9.6 
Map2k3     -3.6 *** -2 
Map2k4     -2.5 * -4.7 
Map3k1     -2.8 *   
Map3k7         -4.3 
Mapk9     -4 *** -6.5 
Il-6ra     -7.6 ** -234 
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3.4.2.1.  Toll-like receptors (TLRs) 
Bone marrow-derived DCs expressed higher levels of genes for TLRs 2,4,8 and 9 
than TLRs 1,5 and 7; however, tlr3 was not expressed.  Tlr2 and tlr5 were upregulated 
upon E-fNE stimulation after 2h.  Then at 24h, tlr(1,2,4,7,8,9)  were all downregulated 
with tlr8 showing a striking 299-fold decrease.  At 48h, tlr(1,2,5,7,8,9) all decreased with 
tlr8 at 228-fold below untreated DCs.   
3.4.2.2.  TLR adaptors and interacting proteins 
At 2h, several adaptor molecules commonly associated with TLR2 were 
upregulated (ripk2, cd14, hspa1a) (Zhang et al., 2009); while tirap and ly96 (MD2), 
which are commonly associated with TLR4, were downregulated.  
By 24h, only hspa1a remained upregulated, and was joined by tollip, known to diminish 
TLR2 and TLR4 responses in mammals.  Many other adaptors were downregulated (ly86 
(MD1), btk, myd88, tirap, and ticam2).  These genes were still downregulated at 48h and 
were joined by cd14 and ly96.  Hspa1a on the other hand, exponentially increased 560-
fold. 
3.4.2.3.  Cytoplasmic effectors 
The only upregulated gene in the effector group was traf6, which was upregulated 
at 2h.  And by 24h, most effectors were downregulated including casp8, fadd, irak1, 
map3k7, eif2ak2, ube2v1 and ube2n.  At 48h, casp8, fadd, irak1, map3k7, and eif2ak2 
remain decreased. 
3.4.2.4.  NFκB pathway and target genes 
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At 2h, nfkb1 and nfkb2 were upregulated by E-fNE treated DCs, along with the 
inhibitors, nfkbia, nfkbib, nfkbil1, and tnfaip3.  Expression of cytokines il-6, il-1a, il-1b, 
il-10 and ifnβ1 were also increased at 2h. Ccl2 was the only gene significantly 
downregulated at 2h. 
By 24h, ifnβ1 increased 158-fold compared to untreated DCs, and nfkbib, il-6, il-
10, and rel expression remained upregulated.  Downregulated genes include tnf (15.4-fold 
reduction), il-1r1, ikbkb (IKK-β), tnfrsf1a, and map3k1 (MEKK-1). 
The only cytokines remaining increased at 48h include ifnβ1, which exponentially 
increased 1596-fold above untreated DCs, and il-6, which remained steady.  Tnfaip3 and 
nfkbia inhibitors were also upregulated at 48h.  Several cytokines were downregulated 
(il-1a, il-1b, ccl2) along with ikbkb (IKK-β), il-1r1 and tnfrsf1a. 
3.4.2.5.  JNK/p38 pathway 
E-fNE treatment of DCs resulted in increased mapk8 (JNK1) and jun expression 
by 2h.  By 24h, jun remained upregulated, but most of the p38 pathway genes were 
downregulated including, mapk9 (JNK2), map2k3 (MKK-3), map2k4 (MKK-4), map3k1 
(MEKK-1), elk1 and fos).  All but map3k1 and elk1 remained downregulated at 48h, but 
were replaced by map3k7. 
3.4.2.6.  NF/IL-6 pathway 
The NF/IL-6 transcription factor is responsible for stimulating the promoter 
region of the COX-2 (ptgs2) gene.  Ptgs2 had the largest increase at 2h and 24h for all 
genes in this pathway (83- and 268-fold, correspondingly).  Clec4e and cebpb (CRP2) 
were increased at 2 and 24h, respectively.  And only ptgs2 remained upregulated at 48h.  
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Il-6ra, on the other hand, was the only gene downregulated in this pathway with a 7.6-
fold decrease at 24h and 234-fold at 48h. 
3.4.2.7.  Co-stimulatory markers 
The gene for cd80 was minimally increased at 2h, and both cd80 and cd86 were 
slightly induced from 24-48h. 
3.4.3.  FACS Analysis 
When treating DCs with Noni, we observed a striking difference in cell adherence as well 
as the monolayer morphology compared to untreated DCs and DCs treated with LPS.  
These Noni-treated cells became very sticky even after only 2h treatment, and in most 
instances, cell scraping was required to collect enough cells for further experiments.  This 
prompted further investigation to determine the phenotype of the cell population used in 
these studies.  Non-stimulated DCs were harvested after 7 days of culture, res spended in 
DC media and treated for 24h with fNE, E-fNE, LPS, E-fNE plus simultaneous addition 
of LPS, or LPS for 24h then fNE or E-fNE for an additional 24h.  Fluorescent-labeled 
antibody staining was performed and analysis was carried out on the FACS Caliber.  The 
results were confirmed in duplicate or triplicate runs. 
3.4.3.1.  Fermented Noni exudate (fNE) 
Around 85% of the cells from all treatments were CD11c+.  DCs treated with fNE 
minimally increased CD11c+Mac-3+ cells by 6%, and a small increase was seen in the 
CD11c+CD62L+ population, compared to both DC and LPS controls (Figure 3.7).  
However, CD83 expression doubled, similar to the LPS control, and CD40 expression 
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quadrupled, although remaining 20% lower than LPS stimulated DCs.  The 
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 Figure 3.7:  Surface marker expression of dendritic cells treated with Noni or 
Entotoxin-depleted Noni compared to LPS.  BMDCs were treated with 5% 
Noni, 5% endotoxin-depleted Noni or 100ng/ml LPS for 24h, then stained with 
corresponding FITC- or PE-conjugated antibodies. (A) Non-stimulated CD11c+ 
BMDCs expressed low levels of CD83, Mac-3, CD62L and CD40.  (B) Noni 
treated cells expressed slightly elevated levels of CD83, Mac-3, and CD62L, but a 
large increase in CD40.  (C) Endotoxin-depleted Noni stimulated a large increase 
in Mac-3 and CD62L with only a moderate increase in CD40, and no change in 
CD83.  (D) LPS stimulated the largest increase in CD83 and CD40, however 
there was no change in Mac-3, and a minimal increase in CD62L.  All 




3.4.3.2.  Entotoxin-depleted fermented Noni exudate (E-fNE) 
This visual phenomenon was observed for both fNE and endotoxin-removed fNE, 
so we examined the surface phenotype of E-fNE-treated DCs as well.  An even larger 
proportion became CD11c+Mac-3+, a striking 66% of the total cell population.  And the 
CD62L+ cells increased from 1.5% in the DC control (4% in the LPS control) to 30% 
(Figure 3.7).  CD11c+CD83+ cells remained the same after treatment with E-fNE; 
however, CD40 expression doubled.  The CD11c+Gr1+B220+ population nearly doubled 
compared to the LPS control.  Interestingly, E-fNE-treated cells slightly increased 
expression of MHC class I molecule. 
3.4.3.3.  E-fNE with LPS (E-fNE + LPS) 
To determine if endotoxin removal was responsible for the large increase in 
Mac3+ or CD62L+ cells, and to assess its requirement for CD40 stimulation, we incubated 
DCs simultaneously with E-fNE and LPS for 24h.  This appeared to have no effect on 
Mac-3+ cells, and a very mild effect on CD62L+ cells; however, CD40 expression was 
increased to nearly that of LPS treated cells (Figure 3.8).  Hence, LPS is necessary for 
induction of CD40, but it does not significantly hinder the E-fNE induced differentiation 
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Figure 3.8:  Surface marker expression of dendritic cells treated with Noni or 
Endotoxin-depleted Noni and simultaneous addition of LPS.  BMDCs were 
treated with 5% Noni or 5% endotoxin-depleted Noni along with 100ng/ml LPS for 
24h, then stained with corresponding FITC- or PE-conjugated antibodies.  The 
addition of LPS was not sufficient to block the transformation to Mac-3+ cells in 
endotoxin-depleded Noni stimulated DCs.  Although, it significantly increased 
expression of CD40 for both Noni and endotoxin-depleted Noni samples.  
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3.4.3.4.  fNE post-LPS 
Since immature DCs are known to have a high degree of plasticity, we decided to 
mature DCs with LPS for 24h, followed by a 24h fNE treatment to determine the strength 
of Noni’s effect on matured DCs.  Indeed, maturation of DCs with LPS was not sufficient 
in blocking the differentiation of DCs to Mac-3+ or CD62L+ cells by fNE, nor did it alter
the expression of CD83+ cells (Figure 3.9).  The only marker affected by LPS treatment 





















Figure 3.9:  Surface marker expression of dendritic cells treated with Noni or 
Entotoxin-depleted Noni, pre-treated with LPS.  BMDCs were treated with 
100ng/ml LPS for 24h, then subsequently with 5% Noni or 5% endotoxin-depleted 
Noni for an additional 24h, and stained with corresponding FITC- or PE-conjugated 
antibodies.  Pre-treatment of DCs with LPS was not sufficient to block the 
development of Mac-3+ cells for endotoxin-depleted Noni-treated DCs, and in fact, 
appeared to augment the expression of Mac-3 for Noni-treated DCs.  LPS was 
responsible for the large increase in CD40.  
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3.4.3.5.  E-fNE post-LPS 
LPS pre-treatment did not hamper the ability of E-fNE to increase Mac-3+ or 
CD62L+ cells either.  In fact, Mac-3+ cells actually increased compared to E-fNE treated 
DCs alone.  CD83 and MHC-I expression remained unchanged compared to fNE 
treatment; however, the CD11c+Gr1+B220+ population minimally increased to its highest, 
35% of the total cell population.  Again, CD40 expression was increased to levels near 
that of the LPS control, which were much higher than E-fNE-treated cells.   
Here we show that LPS-matured DCs are not terminally differentiated, as they are 
affected by fNE or E-fNE treatment to trans-differentiate from CD11c+CD83hiMac-3lo 
population to CD11c+CD83loMac-3hi population with an increasing population of 
CD11c+Gr1+B220+ cells.   
3.5.  Discussion 
Overall BMDC treatment with Noni muted the level of inflammatory signaling compared 
to proportionate levels of LPS.  By removing endotoxin from Noni (E-fNE), there was a 
shift from an early mild inflammatory response in BMDCs followed by a time-dependent 
increase in anti-inflammatory mediators.  Endotoxin removal of Noni not only 
encumbered expression of tn , il-6, ptgs2, ccl3, and ccl5 initiated by fNE, but actually 
caused a decrease in their expression by at least 72h.  This arrest of inflammatory factors 
was confirmed with real-time PCR arrays and revealed the eventual switch to anti-
inflammatory mediators with time. 
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3.5.1.  fNE and E-fNE decrease inflammatory mediators 
In our experiments, fNE caused a decrease in tnf, il-6, ptgs2, ccl3 and ccl5 
compared to LPS controls, and upon removal of endotoxin, this decrease was even more 
evident.  It is possible this is achieved simply through a unique combination of pattern 
recognition receptor (PRR) signaling brought about by the plethora of microbial 
degradation compounds within fNE.  Many microorganisms have been cultured from 
non-pasteurized Noni juice, including E. coli; however, upon fermentation there remains 
only one surviving microbe (personal communication).  This plethora of microbial by-
products may induce a combination of receptors to limit production of genes involved 
with inflammation.  
Some of the most popular traditional uses of Noni targeted inflammation, where it 
was often applied topically to treat arthritis, inflammation due to sprains or broken b nes, 
general pains, and even taken internally to treat asthma (Wang et l., 2002) (Pawlus et 
al., 2007).  With its resurgence in popularity as an herbal tonic, more research has been 
conducted to identify components of Noni responsible for these effects.  Constituents of 
Noni fruit have previously been implicated in reducing inflammatory cytokines and 
inhibiting 5-lipoxygenase activity (Wang et al., 2002) (Deng et al., 2007).  Furthermore, 
Hiruzimi and Furusawa demonstrated that fermented Noni-ppt induced macrophage cells 
to produce lower levels of TNF-α and IL-1b than LPS-induced cells; and IL-10 
production was consistent between the two groups.  These Noni-induced macrophage 
cells were also responsible for the enhanced survival of mice with LLC tumors (Hirazumi 
et al., 1999).  Our results similarly show that tnf is produced at much lower levels than 
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LPS stimulated BMDCs (Figure 3.1), and by 24h it is actually downregulated (tnf levels 
are below control levels); and il-1a and il-1b were stimulated early (Table 3.1) but by 48h 
were also below control levels (Table 3.2).  More recently, Palu et al reported Tahitian 
Noni Juice precipitate was shown to activate cannabinoid receptors, specifically CB2 
(Palu et al., 2008).  This receptor is found mainly in T cells, macrophages and B cells, as 
well as other hematopoietic cells and is responsible for mediating protective signals 
against inflammatory responses (Massa etl al., 2004).  It has also been found that 
Echinacea and several other botanicals activate CB2 receptors (Raduner t al., 2006; 
Woelkart et al., 2008).  These data support our findings that Noni-stimulated BMDCs 
decrease inflammatory mediators.  One mechanism of action may be their ability to 
activate CB2 receptors.  
3.5.2.  Endotoxin-depleted Noni up-regulates anti-inflammatory mediators 
Noni was observed not only to down-regulate inflammatory cytokines, but also to 
up-regulate anti-inflammatory mediators.  With time, endotoxin-removed Noni increased 
levels of anti-inflammatory mediators in BMDCs such as ifnβ1 and hspa1a (Table 3.1), 
while concomitantly decreasing inflammatory mediators (Table 3.2).  Both IFN-β and 
HSP70 are implicated in treating chronic inflammatory maladies (Musch et al., 2007; 
Olofsson et al., 2007; Corr et al., 2009; Tao et al., 2009; Tanaka et al., 2007) (Pockley et 
al., 2008).  Type I IFNs are capable of anti-proliferative effects and often mediate 
hematopoietic suppressive signals (Platanias et l., 2005).  It has been shown that Type I 
IFNs increase NK cell activity, enhance phagocytic abilities of APCs, and promote 
cytotoxic properties of stimulated lymphocytes (Borden et al., 1998) (Sato et al., 2001).  
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HSP70 was also demonstrated to activate NK cells (Multhoff et al., 1997; Gross et al., 
2003) via TLR2 and TLR4 (Asea et al., 2002).  Recently, Li and colleagues reported the 
necessity of NK cells and T cells for the tumor killing and preventative properties of 
Noni (Li et al., 2008).  Similarly, Furusawa et al attributed the anticancer properties of 
Noni-ppt to macrophages, NK cells and T cells (Furusawa et al., 2003).  Our data, 
revealing Noni-induced BMDCs increase production of ifnb1 and hspa1a, may shed light 
on the anti-cancer mechanisms of Noni observed by these studies.  
Besides its NK-activating effects, HSP70 has been implicated as an anti-apop otic 
and anti-inflammatory mediator (Hall et al., 1994) (Yenari et al., 2005) and there are 
several studies involving its use as an adjuvant for cancer therapies (Zhang et al., 2007i; 
Kumar et al., 2009; Wu et al., 2005).  Recently it has been implicated in the protection 
from inflammatory-drug induced colon cancer in a mouse model for inflammatory bowel
disease cancer (Tao et al., 2009).  On a mechanistic level, HSP induction inhibits pro-
inflammatory cytokines by inhibiting NFκB.  This inhibition is through the stabilization 
of IkB; however the exact mechanism is still not clear (Yoo et al., 2000; Schell et al., 
2005).  Hspa1a levels increase drastically with time in endotoxin-removed Noni-treated 
DCs (Table 3.1), which may be partially responsible for the latent commitment o a i-
inflammation.  Since IkBa (nfkbia) levels are increased at 2 and 24h (Table 3.1), HSP70 
may be essential for their stability and suppression of NFκB inflammatory responses.  It 
was recently reported that the anti-inflammatory effects of HSP70 were critically 
dependent on IL-10 (Wieten et al., 2009).  And our data revealed il-10 gene expression 
was also elevated in BMDCs treated with endotoxin-removed Noni.  Noni induction of 
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hspa1as a role in the inhibition of NFκB-mediated inflammation should be further 
investigated.  The involvement of HSP70 in the stabilization of IkB and subsequent 
inhibition of NFκB should be examined.  
3.5.3.  E-fNE inhibition of NFκB 
There has been long standing evidence for the association of inflammation and 
cancer, and NFκB transcription factors are responsible for the production of many 
inflammatory genes.  TNF-α, IL-1 and IL-6 are programmed by the classical NFκB 
pathway and are associated with cancer progression (Karin et al., 2005).  IL-6 in 
particular is associated with unfavorable prognosis in breast cancer recurrence (Zhang et 
al., 1999).  These inflammatory mediators are hijacked by the tumor microenvironment 
to their own advantage, recruiting innate immune cells such as TAMs (tumor associated 
macrophages), tolerogenic DCs and regulatory T-cells to perpetuate this inflammatory 
environment, allowing for angiogenesis and metastasis.  In congruence with the negative 
association of inflammation and cancer progression, long-term use of NSAIDs (non-
steroidal anti-inflammatories), both manufactured drugs and natural remedies, hav  been 
linked to reduced incidence of certain inflammation-associated cancers (Jacobs et al., 
2005; Fairfield et al., 2002; Corley et al., 2003).  NSAIDs and botanicals such as green 
tea, resveratrol and curcumin all have been shown to inhibit NFκB (Siddiqui et al., 2008; 
Majumdar et al., 2009; Aggarwal et al., 2004; Aggarwal et al., 2003).  Our results show 
that although fNE induces cytokine gene expression, its levels of tnf, il-1 and il-6 are 
much lower than LPS.  Noni’s immunomodulatory properties may regulate the immune 
system in a way that favors anti-tumor activity via inhibition of NFκB. 
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Our data show a clear trend in NFκB inhibition by E-fNE.  Not only are NFκB 
inhibitors (nfkbia, nfkbib, nfkbil1, tollip, tnfaip3) increased, but ikbkb (IKK-β) is 
significantly downregulated.  Tollip is an inhibitor of IRAK-1 activation, however, once 
TLR ligands are recognized and TLRs dimerize, Tollip is released and IRAK-4 is capable 
of activating IRAK-1 (Figure 3.10).  Pellino is recruited with TRAF-6 to form a 
membrane complex (II) with TAB/TAK, then it causes poly-ubiquitination with 
subsequent degradation of IRAK-1, releasing Complex III into the cytosol.   TAK1 then 
activates IKKs and MKKs.  IKK-β is responsible for phosphorylating IκB and thus 
releasing NFκB dimers to enter the nucleus.  As seen in Tables 1 and 2, many of these 
NFκB cascade genes are downregulated.  This NFκB inhibition could be one explanation 
for anti-tumor and antiangiogenic properties of Noni, by limiting inflammatory immune 
cell proliferation and lifting the suppression of apoptosis.   This may also explain why 























































































































Figure 3.10:  Toll-like receptor signaling cascade.  Upon engagement of TLR ligand, 
receptors dimerize.  This dimerization brings their cytoplasmic tails together where TIR 
domains can interact.  IRAK4 and IRAK1 are brought together and IRAK4 
phosphorylates IRAK1, allowing for the release of Tollip and its activation.  Once 
IRAK1 is activated, it is released from the receptor tail and binds to the TAK/TAB 
membrane-bound complex. Pellino1 is a scaffold protein responsible for bringing TRAF6 
to the IRAK1/TAK/TAB complex.  Pellino ubiquitinates IRAK1, allowing for its
proteasomal degradation and subsequent release of the TAK/TAB/TRAF6 complex.  
Upon complex formation, TAK1 is activated and phosphorylates IKKs, which in turn 
phosphorylate IκBs.  Phosphorylated IκBs are targeted for proteasomal degradation, 
which releases the NFκB subunits and allows for their nuclear transmigration.  Activated 







Experiments performed by Kawamur and colleagues presented antithetical 
properties of Agaricus blazei-treated BMDCs similar to the results we observed with 
Noni-treated BMDCs.  A. blazei, an edible mushroom often consumed for purported 
health benefits, activated DC maturation with respect to co-stimulatory and MHC 
molecules; however, inflammatory cytokine production was reduced when DCs were 
treated with A. blazei prior to LPS.  This phenomenon was related to its capacity to 
inhibit NFκB.  Interestingly, A. blazei-treated DCs, although suppressing TH1 cytokines 
(IL-12p40), increased TH1 cell development and subsequent IFN-γ production in an 
allogenic mixed lymphocyte reaction assay (Kawamura et al., 2005).  These results are 
similar to what we have observed with Noni-treated BMDCs and again point to the 
inhibition of NFκB as a major mechanism of immunomodulation. 
3.5.4.  Cell surface expression of Noni-treated BMDCs. 
Interestingly, we observed a strange phenomenon with the morphology and cell 
adhesiveness of Noni-treated BMDCs.  The underlying supportive monolayer in the 
cultured bone marrow cells became elongated and much denser than in LPS or untreated 
bone marrow cell cultures.  When trying to collect these cells, they were much ore 
difficult to harvest than typical non-stimulated BMDCs or even LPS-stimulated BMDCs.  
After staining for several bone marrow-derived cell markers, we learned that our Noni-
treated cell population had an increasing amount of Mac-3+ cells.  This effect was most 
prominent in endotoxin-removed Noni-treated BMDCs.  Simultaneous stimulation of 
BMDCs with endotoxin-removed Noni and LPS did not abrogate this differentiation to 
Mac-3+ cells, but in fact slightly enhanced it.  Since non-stimulated BMDCs are known to 
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be very plastic, we then incubated the cells with LPS for 24h prior to endotoxin-removed 
Noni treatment, but observed a nearly identical level of Mac-3+ cells as the original 
endotoxin-removed Noni-treated BMDCs.  The treatment groups highly positive for 
Mac-3 also had a large increase in CD62L+ cells.  Is it possible that endotoxin-removed 
Noni is capable of transforming DCs into CD62L+ monocytes and allowing for their 
subsequent differentiation into Mac-3+ cells?  This marvel encourages more research to 
determine a more precise phenotype of these purported macrophage cells and to elicit the
pathway by which Noni influences matured DCs to become macrophage-like cells. 
3.6.  Conclusion 
With this study we hope to shed light on some of the anti-inflammatory and 
anticancer mechanisms of Noni, in order to better understand this product that has held 
long-standing native use for the treatment of many ailments and is receiving a resurgence 
in popularity with the advent of Tahitian Noni ® and its approval by the European Food 
and Safety Authority (European Food Safety Authority, 2009).  Noni elicits an early mild 
inflammatory response in BMDCs, followed by an anti-inflammatory respon e triggered 
by high levels of ifnβ1 and hspa1a production and NFκB inhibitors.  This divergent 
occurrence of pro- and anti-inflammatory mediators may give a unique rise to TH1
immunity while quenching the undesirable effects of prolonged inflammation.  It also 
causes trans-differentiation of BMDCs into macrophage-like cells expressing Mac-3.  
Further research is needed to determine whether these anti-inflammatory ediators are 
indeed players in the anticancer effects of Noni.  And further investigation in  the 
known and unknown NFκB inhibitory compounds in Noni would be of great value. 
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SUMMARY 
 Since their discovery as mediators of innate and adaptive immunity, dendritic 
cells have been fervently researched.  Their ability to enhance innate mediators such as 
NK cells, as well as process and present antigen to lymphocytes has led to their use in 
many immunotherapies.  Scientists have put great effort into understanding their complex 
nature in order to harness their power for enhancing or even distinguishing immune 
responses.  In this study, we have examined DCs in two different settings.  First, we 
observed the influence of fusion with tumor cells; and second, we tested the effects of 
Morinda citrifolia on DCs.   
 In the first experiment, either immature or mature DCs were chemically fused 
with tumor cells and their expression of inflammatory chemokine (CCL), chemokine 
receptors (CCRs), and several other DC markers was evaluated.  In immature DCs, fusion 
induced maturation with respect to CCLs, CCRs, and typical DC maturation markers; 
however, mature DCs used for fusion, which already expressed the aforementioned 
markers prior to fusion, proceeded to down-regulate CCLs, CCRs, and other markers of 
maturation.  This peculiar phenomenon of ‘de-maturation’ of DCs clarifies the need for 
immature DCs utilized in tumor fusion procedures.  This is essential in order to have the 
most effective DC-tumor hybridoma vaccine capable of migration to secondary lymph 
tissues where they will be most effective at eliciting cell-mediate responses against DC 
presented tumor antigens. 
 The second experiment was aimed at expanding the knowledge of Noni as an 
immunomodulator.  Noni’s popularity as a dietary supplement and immune enhancer is 
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growing, and it is important to understand the mechanisms behind its purported actions.  
It is a known activator of DCs, and consists of a wide variety of PAMPs from killed
microflora after fermentation.  So, we tested the ability of Noni to activate DCs via TLRs.  
By analyzing genes in the TLR signaling pathway via real-time RT-PCR, we observed 
that Noni stimulated production of anti-inflammatory mediators as well as inhibiti g 
pathways downstream of TLRs, including NFκB.  And an interesting find was that Noni-
treated DCs may actually have trans-differentiated into macrophage cells.   
 Overall, DCs were shown to be activated by fusion to tumor cells and treatment 
with Noni.  Further experiments to confirm these findings at the protein level would be 
advantageous.  Chemotactic assays would benefit the first experiment.  And further 
investigation of the Noni-induced trans-differentiation of DCs into macrophages would 
be of great interest.  Lastly, since NFκB inhibitors are generating much attention with 
respect to anti-inflammation and anticancer therapies, the role of Noni and NFκB 
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